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ABSTRACT
ANALYSIS OF CHRNA5 ISOFORMS IN BREAST CANCER
CELL LINES IN RESPONSE TO SERUM STARVATION AND
ESTROGEN TREATMENT
Azer Aylin Açıkgöz
MSc. in Molecular Biology and Genetics
Supervisor: Asst. Prof. Dr. Özlen Konu
August 2013
Breast cancer is a complex disease that can be classified into distinct molec-
ular subtypes including Basal, Luminal A, Luminal B and HER2 positive.
These molecular subtypes mainly differ in their hormone receptor expression
and response to treatment. This makes the discovery of new molecular mark-
ers for further classification important. Cholinergic nicotinic acetylcholine
receptors are ion channels involved in smoking behavior, neurodegenera-
tive diseases and cancer. Cholinergic nicotinic receptor alpha 5 (CHRNA5)
has been associated with nicotine addiction and recently with lung cancer
yet its importance in breast cancer remains relatively unexplored. In the
present study, a panel of 10 breast cancer cell lines were used for quan-
tification of isoform-specific CHRNA5 expression using qPCR. Changes in
CHRNA5 expression in response to serum starvation and estrogen treatment
were assessed. qPCR showed that CHRNA5 was alternatively spliced, with
at least five different isoforms in breast cancer cell lines. qPCR analysis for
CHRNA5 expression in serum treated and serum starved cells were analyzed
after outlier detection and exclusion; and statistical tests included ANCOVA
using geometric mean of TPT1 and SDHA, as reference genes. Our results
demonstrated that, CHRNA5 expression differed between different subtypes
of breast cancer cell lines. CHRNA5 expression significantly responded to
serum starvation in ZR75-1 and MDA-MB-157 cell lines, isoform specifically.
Isoform expression of CHRNA5 exhibited significant alterations upon estro-
gen treatment in a dose and time-dependent manner. Expression of 1000bp
variant, isoform2 and isoform3 of CHRNA5 significantly increased upon E2
ii
treatment and total CHRNA5 and isoform2 CHRNA5 increased in expres-
sion at 24 hours when compared with 12 hours of treatment. Our findings
show that CHRNA5 has multiple isoforms in breast cancer, with potential to
be modulated by serum starvation and estrogen treatment in a cell-specific
manner.
Keywords: Breast cancer, CHRNA5, estrogen, serum starvation, molecular
subtype.
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ÖZ
CHRNA5 İFADESİNİN MEME KANSERİ HÜCRE
HATLARINDA ANALİZİ VE SERUM AÇLIĞI İLE
ÖSTROJENE CEVABI
Azer Aylin Açıkgöz
Moleküler Biyoloji ve Genetik Yüksek Lisansı Tez Danışmanı:
Yrd. Doç. Dr. Özlen Konu
Ağustos 2013
Meme kanseri karmaşık bir hastalık olup, moleküler olarak bazal, luminal
A, luminal B, HER2+ ve normal tipler olarak sınıflandırılabilir. Bu tipler
arasındaki ana fark hormon reseprörlerinin ifadeleri açısındandır. Farklı tip-
lerin tedaviye cevapları da farklıdır. Bu nedenle, meme kanserini daha iyi
sınıflandırabılmek için yeni moleküler markörler bulmanın önemi artmak-
tadır. Kolinerjik nikotinik asetilkolin reseptörleri , sigara içme alışkanlığında,
nörodejeneretiv hastalıklarda ve kanserde rolü olduğu düşülünen iyon kanal-
larıdır. Kolinerjik reseptör nikotinik alfa 5 (CHRNA5) nikotin bağımlılığı
ve akciğer kanseri ile ilişkilendirilmiştir ancak meme kanserindeki önemi
henüz bilinmemektedir. Bu çalışmada, 10 adet meme kanseri hücre hat-
tından oluşan bir panel kullanılarak, CHRNA5 varyantlarının ifadesi qPCR
ile ölçülmüştür. CHRNA5 ifasesinin serum açlığı ve östrojen tedavisine bağlı
değişimi incelenmiştir. qPCR sonuçları CHRNA5in meme kanseri hücre hat-
larında alternatif kırpıldığını ve en az beş izoforma sahip olduğunu göster-
miştir. Serum varlığında ve serum açlığında CHRNA5 ifadesini ölçen qPCR
verilerinin analizleri aykırı verilerin bulunup çıkartılmasından sonra, TPT1 ve
SDHA referans genlerinin geometrik ortalaması alınarak ANCOVA istatistik-
sel analizi ile yapılmıştır. Sonuçlarımız gösteriyor ki, CHRNA5 ifadesi farklı
tip meme kanseri hücre hatları arasında farklılık göstermektedir. Serum
yokluğunda ZR-75-1 ve MDA MB 157 hücre hatlarında CHRNA5 ifadesi
izoformlara özgü olarak anlamli bir değişime uğramıştır. Östrojen tedavisi
sonucunda, CHRNA5 izoformlarının ifadeleri doz ve zamana bağlı olarak
değişmektedir. Toplam CHRNA5 ifadesi ve izoform 2 CHRNA5 ifadesi 24
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saatte, 12 saate göre artış göstermiştir. Bulgularımız CHRNA5in meme
kanserinde birden fazla izoformu olduğunu ve bu izoformların serum açlığı
ve östrojen tedavisi sonucunda, hücre hattına bağlı olarak değişme potan-
siyelinin olduğunu göstermiştir.
Anahtar sözcükler: meme kanseri, CHRNA5, alternatif kırpılma, östrojen,
serum açlığı, moleküler tip.
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Chapter 1
INTRODUCTION
1.1 Breast Cancer
Breast cancer is the most common cancer among females. In the USA, breast
cancer constitutes 28% of all new cancer cases and 26% of cancer-related
deaths in women.1
1.1.1 Types and Progression
Breast cancer can either be hereditary or sporadic. In hereditary breast can-
cer, patients have susceptibility to breast cancer due to a germline mutation
that they inherited. The major genes that result in susceptibility are BRCA1
and BRCA2 but mutations in PTEN and TP53 can also cause breast can-
cer.2 The contributions of mutations of particular genes to susceptibility of
hereditary breast cancer are shown in Figure 1.1. Sporadic breast cancer
occurs as a result of the accumulation of mutations in somatic tissues.2,3
1
Figure 1.1: The genetics of breast cancer. (Reproduced with permission from
Wooster et al., 2003 Copyright Massachusetts Medical Society)
The transformation from a normal cell to a malignant cell can be described in
3 steps. In step 1, which is named ‘carcinoma in situ’, a normal cell changes
into an atypical cell type and, after successive divisions, becomes a lesion.
Step 2 is where the lesion becomes malignant and step 3 is the formation of
metastases.3
1.1.2 Genes Involved in Breast Cancer
The genes implicated in breast cancer tumorigenesis can be divided into
6 groups. Oncogenes (e.g. MYC, ERBB2), tumor suppressor genes (e.g.
BRCA1, BRCA2, p53), apoptosis genes, steroid receptors (e.g. ERα, ERβ,
PR) and genes involved in invasion/cell adhesion and angiogenesis.3
1.1.3 Risk Factors
The major breast cancer risk factors are gender and age. Although familial
breast cancers constitute around 10% of all breast cancers, family history is
also an important risk factor, with increasing susceptibility to breast cancer
in women with one or more relatives with breast cancer.
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Hormonal and reproductive risk factors include the main female hormone
estrogen and lack of childbearing at an early age. Early menarche and late
menopause are also thought to increase the risk of getting breast cancer in
women.4
Other major and minor risk factors include usage of hormone replacement
therapy or oral contraceptives, lack of physical activity during adolescence,
weight gain after menopause, obesity, history of some non-malignant breast
diseases, environmental factors such as diet, consumption of alcohol on a
daily basis and exposure to radiation.4
1.1.4 Classification
Classification of breast cancer is done in several categories in order to decide
on the best treatment approach. The most common ones among these cat-
egories are the histopathological type, tumor grade, tumor stage, receptor
status and classifications that are based on DNA.
1.1.4.1 Histopathological Type
Histopathological type is defined based on the growth pattern of the breast
cancer, with the most common type being invasive ductal carcinoma or IDC.
There are, at least, 17 different histopathological types of breast cancer.5
1.1.4.2 Tumor Grade
The grading of the breast cancer tumors is based on the comparison of the
appearance of the tumor tissue with the normal breast tissue under the mi-
croscope. Three different criteria are assessed and a score from 1 to 3 is given
for each of them. The grade of the tumor is identified after the summation
of the scores for each criteria. 3 to 5 points indicate that the tumor is well-
differentiated (low grade), 6 to 7 points indicate that the tumor is moderately
differentiated (intermediate grade) and 8 to 9 points indicate that the tumor
is poorly differentiated (high grade). The histological grades are generally
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correlated with the prognosis of breast cancer, with the poorly differentiated
high grade tumors having the worst prognosis.6
1.1.4.3 Tumor Stage
Tumor staging is the procedure by which the location and the size of the
cancer is determined. Staging is done after the assessment of mainly three
properties which are tumor size (T), the involvement of lymph-nodes (N)
and the presence of metastasis (M). This method, called the TNM staging
system, is also used in the decision of the appropriate treatment for a patient
and informs clinicians about the severity of the disease.7,8 Stages differ from
0 to IV, with stage II and stage III having substages and stage IV being
the most advanced stage, generally considered incurable. A larger tumor
size, spreading to a number of nodes and metastasis tend to have a worse
prognosis.7,8
1.1.5 Receptor Status and Molecular Subtype
Another category used to classify breast cancer is its receptor status. Ex-
pression, or lack thereof, of three most important ones, estrogen receptor
(ER), progesterone receptor (PR) and HER2, helps in the determination of
appropriate treatment type.
It was found out that breast tumors and breast cancer cell lines could be
clustered into different subtypes according to the similarities and differences
in their gene expression patterns. After microarray analysis, breast cancer
was divided into four distinct molecular subtypes, namely luminal (ER+),
basal (ER-, also called triple-negative breast cancer), ERB-B2+ (HER2+),
and normal-like. Luminal type is further divided into luminal A and luminal
B, with distinctive gene expression patterns.9–12
These molecular subtypes have different clinical outcomes and prognosis,
with basal type having the worst prognosis and ERB-B2 having a consider-
ably bad prognosis.9–12
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1.1.6 Estrogen, Estrogen Receptor (ER) and Breast
Cancer
Estrogens are the primary steroid hormones of females. Premenopausal
women have high levels of serum estrogen, but this level decreases after
menopause. Estrogen can be endogenous or exogenous. Exogenous sources
include hormone-replacement therapies and oral contraceptive usage. Pri-
mary endogenous source of estrogen during the menstrual life are the ovaries.
The small amount of estrogen present postmenopausally comes from extrag-
onadal tissues like muscles, fat and liver.13,14 Sources of estrogen and its
target organs can be seen in Figure 1.2.
Figure 1.2: Sources of estrogen and its target organs. (Reproduced with per-
mission from Clemons et al., 2001 Copyright Massachusetts Medical
Society)
Estrogens go through the cell membrane via passive diffusion. In ER+ cells,
estrogen forms a ligand-receptor complex with nuclear ER and the complex
activates estrogen response elements (ERE). There are two types of estrogen
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receptor, namely ER-α and ER-β. Although ER-α has a higher affinity for
estrogen when compared to ER-β, a balanced ratio between the two types of
receptors is important in determining the estrogen response of a tissue.14,15
Pathways of ER signaling are summarized in Figure 1.3.
Figure 1.3: Estrogen receptor signaling pathways. (Reproduced with permission
from Yager et al., 2006 Copyright Massachusetts Medical Society)
Estrogen is implicated in the carcinogenesis of the breast. In rodents, es-
trogen intake causes mammary tumors, excessive hormone stimulation may
cause uncontrolled cell growth and division, resulting in malignancy.14 The
effects of estrogen are believed to be cumulative; when the exposure time
lengthens, the risk increases. This is supported by the fact that women who
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start their menstrual periods at an earlier age, or go through menopause at a
later age tend to be at a higher risk of breast cancer.13 Hormone replacement
therapy also causes an increase in the breast cancer risk, but this increase
can be reversed.15 Estrogen has been associated both with the initiation and
progression of breast cancer, but the mechanisms underlying this effect are
complex.13–15 Pathways that lead to estrogen carcinogenesis is summarized
in Figure 1.4.
Figure 1.4: Pathways that lead to estrogen carcinogenesis. (Reproduced with
permission from Yager et al., 2006 Copyright Massachusetts Medical
Society)
Estrogens were shown to regulate a variety of target genes. There are three
mechanisms with which estrogen exerts its effects on its target genes.16 These
are:
1. Direct interaction of ER with DNA through estrogen response elements
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2. Recruitment of other transcription factors by ER
3. Indirect modulation
Effects of estrogen on gene expression is thought to be cell specific.16 The
effects of estrogen on proliferation, apoptosis and gene expression were in-
vestigated mainly in ER-responsive (ER+) breast cancer cell lines. In the
ER+ breast cancer cell lines MCF7 and T47D, estrogen treatment resulted
in increased proliferation17,18 but this was not the case in an ER- breast can-
cer cell line MDA MB 436.17 A variety of primary and secondary responses
(either up- or down-regulation) to estrogen treatment were identified in ER+
cell lines. These include genes involved in cell cycle and apoptosis (Cyclin
D1, CDC2, CDC6, MCM2), genes that code for growth factors and cytokines
(IGFBP4, WISP2) and TFF1/PS2, XBP1, CCND1, FOS and E2F.16,19–21
1.1.7 Breast Cancer Cell Lines
A large part of the research on breast cancer relies on the use of breast
cancer cell lines. Breast cancer cell lines are immortalized cell lines, generally
isolated from metastatic breast tumors and they have varying phenotypic and
molecular characteristics, resembling the diversity of breast tumors. The
origins of the cell lines used in this study can be found in Table 1.1.
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Table 1.1: The origins of breast cancer cell lines used in this study.22
Cell Line Source Tumor Age Ethnicity
1 BT-20 PB IDC 74 White
2 HCC 1937 PB DC 24 White
3 MCF7 PE IDC 69 White
4 MDA MB 157 PE MC 44 Black
5 MDA MB 231 PE AC 51 White
6 MDA MB 361 PB AC 40 White
7 MDA MB 453 PE AC 48 White
8 MDA MB 468 PE AC 51 Black
9 T47D PE IDC 54 N/A
10 ZR-75-1 AF IDC 63 White
AC, adenocarcinoma; AF, ascites fluid; DC, ductal carcinoma;
IDC, invasive ductal carcinoma; MC, metaplastic carcinoma;
PB, primary breast; PE, pleural effusion.
Breast cancer cell lines can, like breast cancer tumors, be divided into molec-
ular subtypes, mainly characterized by their expression of hormone receptors
ER, PR and HER2.23 Table 1.2 shows which subtypes express which recep-
tors.
Table 1.2: Hormone receptor characterization of molecular subtypes.23
Subtype ER PR HER2
Basal - - -
Luminal A + + or - -
Luminal B + + or - +
HER2 - - +
According to their expression of these receptors, the 10 breast cancer cell
lines used in this study falls into the following molecular subtypes:22,24,25
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Table 1.3: Molecular characterization of breast cancer cell lines.22,24,25
Cell Line ER PR HER2 Subtype
1 BT-20 - - - Basal
2 HCC 1937 - - - Basal
3 MCF7 + + - Luminal
4 MDA MB 157 - - - Basal
5 MDA MB 231 - - - Basal
6 MDA MB 361 + + + HER2
7 MDA MB 453 - - + HER2
8 MDA MB 468 - - - Basal
9 T47D + + - Luminal
10 ZR-75-1 + + - Luminal
1.2 Cholinergic Receptor Nicotinic Alpha
(CHRNA or nAChR)
Nicotinic acetylcholine receptors or cholinergic nicotinic receptors are excita-
tory, transmembrane ligand-gated ion channels that belong to a superfamily
along with other transmembrane ligand-gated channels such as GABA and
glyR. They can bind acetylcholine (ACh) and nicotine and are mainly found
at the neuromuscular junction and in some neurons both in the central and
the peripheral nervous system.26–28
nAChRs have 2 different types of subunits identified, namely α, β and are
found in either homomeric (consisting of a single subunit) or heteromeric
(consisting of multiple subunits) pentamers. Each of the subunits have 4
transmembrane domains and a long extracellular N-terminal domain. To
date, 9 α subunits (α2-10) and 3 β subunits (β2-4) have been identified,
making a total of 12 subunits.27 Different combinations of these subunits in
pentamers results in receptors with different electrophysiological properties.
Some of the nAChRs were found out to have mRNAs that can be alter-
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natively spliced, which further increases the diversity, with different splice
variants resulting in different receptor subtypes. These subtypes may ex-
plain the variable tolerance and addiction to nicotine or different release of
neurotransmitters in different synapses.26,28
Schematic representation of nAChRs and an example of a heteromeric nAChR
can be seen in Figure 1.5 and 1.6, respectively.
Figure 1.5: Schematic representation of a nAChR. (Reprinted from Improgo et
al., 2010, with permission from Elsevier)
Figure 1.6: Schematic representation of a heteromeric nAChR and ACh bind-
ing site. (Reprinted from Itier et al., 2001, with permission from
Elsevier)
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nAChRs are implicated in a variety of diseases, disorders and behaviors, in-
cluding nicotine addiction and smoking behavior, Alzheimer’s Disease, Parkin-
son’s Disease, schizophrenia, epilepsy, and cancer.26–28
1.3 CHRNA5
nAChR subunits α3, α5 and β4 cluster together in the genome.29,30 These
were later mapped to chromosome 15 in humans (15q24-25) and chromosome
9 in mice.31 Figure 1.7 shows the gene cluster and relative positions of these
three subunits in the genome.
Figure 1.7: Schematic representation of CHRNA3-CHRNA5-CHRNB4 gene
cluster. (Reprinted from Improgo et al., 2010, with permission from
Elsevier)
When combined with α3β3 subunits, α5 subunit has been shown to cause
faster and a higher amount of desensitization of the receptor complex.32,33
CHRNA5 has 6 exons and is alternatively spliced, with at least three alter-
native transcripts identified.34 It is implicated in smoking behavior with a
single nucleotide polymorphism (SNP) and a common haplotype, resulting
in high nicotine dependence and nicotine addiction.35–37 CHRNA5 has also
been associated with cognitive performance38,39
CHRNA5 is implicated in lung cancer37 with at least three independent GWA
studies40–42 showing association between the chromosomal region of this gene
cluster and lung cancer. CHRNA5 was found to be upregulated 30 times in
lung adenocarcinoma, compared to normal lung tissue. 5 different transcripts
of CHRNA5 was identified in normal lung tissue, due to alternative splicing
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of the 5th exon. 1 of these isoforms is the full length CHRNA5 transcript
and the others are shorter versions. All of these variants were expressed sig-
nificantly higher in lung adenocarcinoma.43 Splicing of these isoforms can be
seen in 1.8.
Figure 1.8: Alternative splicing of CHRNA5 in lung. (Reprinted from Falvella
et al., 2013, with permission from Oxford University Press)
CHRNA5 was also shown to be expressed in breast tumors and breast cancer
cell lines.44
1.4 Alternative Splicing
Alternative splicing is the process by which a single gene is allowed to pro-
duce a variety of protein isoforms. This event has a pivotal role in differential
expression of genes. Since eukaryotic genes have introns, pre-mRNA splicing
is necessary to remove intronic sequences and form the functional mRNA,
consisting only of exons. Splicing of the pre-mRNA to the mature mRNA is
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done by a complex called the spliceosome, which includes 5 small nuclear ri-
bonucleoproteins (snRNPs) and a large number of other proteins.45,46 Proper
localization of the spliceosome is also dependent on cis-regulatory elements,
named exonic and intronic splicing enhancers (ESE and ISE) and exonic and
intronic splicing silencers (ESS and ISS), as well as trans regulatory splicing
factors.47
Correct splicing is very important, as errors in parts of this mechanism lead
to a variety of diseases. Especially in genes that are implicated in apop-
tosis, invasion, differentiation and metastasis, splicing occurs differently in
tumors.45,48,49
At least five different alternative splicing patterns were identified.45,49,50
They are shown in Figure 1.9. These include:
1. Cassette Exon: these exons are either skipped during splicing (spliced
out) or included in the mature mRNA.
2. Alternative 3’ Splice Site: an alternative to the normal 3’ splice
junction is used, resulting in an altered 5’ end of the exon that is
downstream. This can either lengthen or shorten the exon. Also called
alternative acceptor site.
3. Alternative 5’ Splice Site: an alternative to the normal 5’ splice
junction is used, resulting in an altered 3’ end of the exon that is
upstream. This can either lengthen or shorten the exon. Also called
alternative donor site.
4. Mutually Exclusive Exons: one of these exons is included in the
processed mRNA after splicing, but never both.
5. Intron Retention: in this pattern, an intron is not removed and
included in the mature mRNA product.
Among these patterns, exon-skipping is the one that is most commonly ob-
served in mammals, while intron retention is the least commonly observed.51
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A combination of different alternative splicing patterns can be used in pro-
cessing of a single pre-mRNA.47 In addition to these main patterns, the
presence of variants may be due to having multiple promoter sequences or
multiple polyadenylation sites. Different isoforms of a gene can also be cel-
l/tissue type or developmental stage-specific.45,47–49 It was shown that the
5th exon of CHRNA5 is an exon with alternative splice sites, and there are
at least 5 isoforms that either include or exclude parts of this exon.43
Figure 1.9: Different types of alternative splicing. (Reprinted from Ladomery et
al., 2006, with permission from Elsevier)
Alterations in splicing patterns of particular genes have been observed or im-
plicated in a number of diseases, including different types of cancer. These
alterations may include mutations in cis or trans regulatory elements of splic-
ing and result in changes in the selection of splice sites, leading to the for-
mation of ‘unnatural’ mature mRNAs that are normally not present in a
specific tissue or to changes in the ratios of natural splice variants in specific
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tissues.46,47 An illustration of how alterations in splicing can lead to malig-
nancy is shown in Figure 1.10.
Figure 1.10: Abnormal pre-mRNA splicing can lead to malignancy. (Reprinted
from Pajares et al., 2007, with permission from Elsevier)
In tumors, these so called ‘abnormal’ splicing variants, or aberrant transcripts
are seen in genes that are involved in many processes in cancer susceptibility,
initiation, development and progression. These include genes that are in-
volved in apoptosis (p53, Klf6, MDM4, Bcl-x, Caspase-2, Fas), metabolism
(Pyruvate kinase M ), invasiveness and metastasis (CD44, FGFs, Rac1, Ron,
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Crk), angiogenesis (VEGFA) and proto-oncogenes (Cyclin D1, H-Ras).46,48,52
Classical methods for identification of splice variants in cancer included
cDNA sequencing and RT-PCR, but recently more global, genome-wide meth-
ods have been devised. These methods include EST alignment, splicing-
specific exon-junction microarrays and bead-based fiber microarrays.46,47,53
1.5 Serum Starvation
For years, serum starvation has been widely used as an experimental proce-
dure, mainly to obtain cells with synchronized cell cycles. Although some
scientists oppose the utility of serum starvation as a method of cell synchro-
nization,54,55 a large number of researchers use this method in order to obtain
cells with a G0/G1 phase arrest in the cell cycle. It is not exactly clear how
serum starvation results in cell cycle arrest, but there has been a number of
explanations. One of these associate the cell cycle arrest with inactivation of
TOR and decreased Cyclin D1 levels, while another links it to increased p21
levels.56,57
Serum starvation has also been related to apoptosis. Prolonged exposure to
serum-free media can cause apoptosis by itself, both in a p53-dependent58
and p53-independent manner.59 A number of caspases were also implicated
in serum starvation induced apoptotic processes.60,61
Apart from being used as a method to synchronize cells, serum starvation has
also been used as a method to investigate apoptosis, stress response of cells,
autophagy and protein degradation, and regulation of gene expression. Mi-
croarrays were used to study molecular mechanisms of serum starvation/de-
pletion (unpublished data from Konu Lab). It is important to note that,
generally, serum starvation response differs between the cells and the cell
culture protocols used.62
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1.6 Quantitative Real Time Polymerase Chain
Reaction (qPCR) Analysis
Quantitative real-time PCR (qPCR) has become the method of choice, both
in research and in clinic, for quantification of gene expression. Among its
many advantages are the fact that it is a high-throughput method, it is
cost-effective, sensitive, specific and relatively easy to perform.63,64 Still, in-
terpreting and analyzing the data can be a challenge due to the complexity
that having a number of variables brings.
Experimental design is very important, starting from the RNA to the analy-
sis of the data obtained from qPCR. The things that need to be considered
include, but are not limited to, RNA isolation and storage, preparation of
the experimental setup, number of replicates (both biological and technical),
normalization and statistical analysis methods.63,64 In order to increase the
statistical significance and meaning of the results, sample size must be in-
creased and both biological and technical replicates must be present. Having
biological replicates are thought to have more value than technical repli-
cates, though technical replicates may help in the identification of outlier
values.65,66 There could be sample to sample or run to run variations be-
tween samples. Normalization is the method used to correct sample to sample
variations that can arise from total RNA converted to cDNA, cDNA conver-
sion efficiency, high individual variation or technical differences among runs
and sampling errors.63,65,67,68 Selecting a proper normalization method is of
great importance since normalization affects the interpretation of the data.
Normalization is generally done by using one or more reference genes. Us-
ing multiple reference genes for normalization is advised, with three being
considered the optimal number.63 When using multiple reference genes, nor-
malization can be done by calculating the geometric mean of the reference
genes. To aid with the selection of reference genes, a number of programs
were devised, including GeNorm and BestKeeper.63,64
qPCR results can sometimes be variable, with the causes for this variabil-
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ity being either biological, technical or due to an inappropriate experimental
design.65 This high number of possible causes for variability makes data anal-
ysis very important in interpreting the result of qPCR. Statistical analysis
of the obtained data aims to identify differences in gene expression that are
truly due to treatment, after minimizing the technical noise and identify the
biological variability of the samples.68 To this end, a proposed list of steps for
data analysis includes the identification and exclusion of outliers (experimen-
tal errors), followed by averaging of technical and biological replicates and
choosing a statistical test to perform.69,70 The presence of three samples was
said to be enough to be able to detect outliers with statistical significance.70
Outliers can be identified as data points that do not obey the distribution of
other data points in the data set. These are considered irregulars, distinct
from the rest of the data set.66 Identification and handling of these outliers
is important to obtain statistically meaningful results and prevent wrong in-
terpretations of the data.
It was proposed that a graphical representation of the distribution of the
data may be of aid in the identification of outlier values.66 To this end, an
easy method was devised using box plots.66 In these boxplots, the median
value of the data points for a set is calculated and a box that represents the
interquartile range is drawn around the median. The data points that fall
outside of the whiskers are marked as potential outliers.66 Statistical anal-
yses, such as Grubb’s test may be needed to assess the significance of the
potential outliers.66 The identified outlier values can later be removed from
the data prior to analysis, increasing the statistical power.
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Chapter 2
AIM
Breast cancer is the most common cancer and the secondary cause of cancer-
related deaths in women in the Western world. This year, in the United
States alone, more than 200000 women are expected to develop breast can-
cer, with an estimated death of around 40000.71 Since breast cancer is a
complex disease, classification has been important in prognosis. Histopatho-
logical type, tumor grading and staging were classically used to classify breast
cancer and help with prognosis, but the observation that breast cancer is a
more complex disease than previously thought lead to molecular classifica-
tion of breast cancer and molecular subtypes.
Molecular subtype is described essentially by hormone receptor status, such
as ER+, PR+, HER2+. According to this classification, breast cancers are
now subdivided to 5 main molecular subtypes. These are basal or triple neg-
ative, luminal A, luminal B, HER2+ and normal-like. Even though this lead
to a better classification, it was seen that there were significant differences
in response to a particular therapy, clinical outcomes and prognosis, even in
patients that are categorized under the same molecular subtype. This calls
for a need for further molecular classification of breast cancer, and makes
finding new molecular markers that can be used in novel categorization of
great importance.
Cholinergic nicotinic receptors (CHRNs) are ion channels that have been as-
sociated with smoking behavior and nicotine addiction, neurodegenerative
diseases and obesity. 9 alpha and 3 beta subunits have been identified in
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humans. Recently, the α5 subunit has been associated with lung cancer. It
was shown that CHRNA5 was expressed in breast cancers, but its transcrip-
tional regulation was not extensively studied. In-silico analyses also suggest
that CHRNA5 expression increases with estrogen treatment in ER+ breast
cancer cell lines.72
Alternative splicing is an important way by which cells can increase their
protein repertoire without the need for extra genes. Alternative splicing pat-
terns of some genes were shown to be aberrant or abnormal in cancers, with
either changes in the splice variants or changes in the ratios between specific
variants.
In light of these information, in this study we asked whether CHRNA5 iso-
forms were alternatively spliced among different breast cancer cell lines under
different serum regimes and whether an estrogen receptor positive cell line,
MCF7, increased its CHRNA5 expression upon estrogen treatment.
In particular, the following were studied:
• Presence of alternative splicing of CHRNA5 in a breast cancer cell line
panel and identification of different splice variants.
• Isoform-specific CHRNA5 expression in breast cancer cell lines with
different molecular subtypes and identifying the relationship, if any,
with ER status.
• The expression profile of CHRNA5 splice variants in breast cancer cell
lines in response to serum starvation treatment.
• Isoform-specific CHRNA5 expression in response to estrogen treatment,
and whether it changes according to dose and time of treatment in
MCF7 cells.
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Chapter 3
MATERIALS AND METHODS
3.1 Cell Culture Protocols
3.1.1 Cell Lines
10 different breast cancer cell lines (MCF7, T-47D, ZR-75-1, MDA-MB-361,
MDA-MB-453, BT-20, HCC 1937, MDA-MB-468, MDA-MB-231, MDA-MB-
157) were used in this study (ATCC; Manassas, USA). They have been cul-
tured in Bilkent University MBG laboratories. Information about these cell
lines are listed in Table 3.1
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3.1.2 Cell Growth Conditions
DMEM (SH30021.01), RPMI 1640 Medium (SH30255.01), FBS (SW30160.03),
Penicillin/Streptomycin Solution (SV30010) and Trypsin/EDTA solution (SH30042.01)
were from HyClone (Logan, USA). Non-essential amino acid solution (K0293)
was from Biochrom AG (Berlin, Germany). PBS (17-516F) was from Lonza
(Switzerland).
The growth medium of MCF7, MDA-MB-453, BT-20, MDA-MB-468 and
MDA-MB-231 cells included DMEM with 10% Fetal Bovine Serum, 1% Peni-
cillin/Streptomycin solution and 1% Non-essential amino acids.
The growth medium of ZR-75-1 cells included RPMI 1640 medium with 10%
Fetal Bovine Serum, 1% Penicillin/Streptomycin solution, 1% Non-essential
amino acids and 4,5 g/L D(+)-Glucose (Riedel-de-Haël, Hanover, Germany).
The growth medium of MDA-MB-361 and MDA-MB-157 cells included DMEM,
with 10% Fetal Bovine Serum, 1% Penicillin/Streptomycin solution, 1% Non-
essential amino acids and 1% Sodium Pyruvate (11360) (Gibco, USA).
3.1.3 Thawing Cells
One vial of frozen cells was taken from liquid nitrogen and were placed in the
water bath at 37°C to melt. After melting, the cells were taken to a 15 ml,
sterile tube with 10 ml complete medium and re-suspended. The cells were
centrifuged at 1500 rpm for 5 minutes. After the supernatant was aspirated,
the cells were re-suspended in complete growth medium and seeded in T25
flasks (Greiner Bio One, Frickenhausen, Germany) with 7-8 ml of complete
medium.
3.1.4 Subculturing of Cells
All cell types were grown in T75 flasks (Grenier Bio One, Frickenhausen,
Germany) with 13-14 ml of complete medium in a 37°C incubator with 5%
CO2. The cells were passaged to new flasks, on average, every 3 days, or when
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they were around 80% confluent. For passaging, the growth medium was
aspirated; flasks were washed with PBS. 0.5 - 1 ml Trypsin/EDTA solution
was then added; flasks were kept in 37°C incubators for 5-8 minutes, until
the cells detached from the surface. The cells were then collected with 7-8 ml
complete growth medium and centrifuged at 1500 rpm for 5 minutes. The
supernatant was aspirated; the cells were re-suspended in complete medium
and were seeded to new flasks with the desired dilution.
3.1.5 Cryopreservation of Cells
For cryopreservation, freezing medium was prepared as 10% DMSO in FBS.
The growth medium was aspirated; cells were washed with PBS, and trypsinized.
After detachment, the cells were collected with complete medium and cen-
trifuged at 1500 rpm for 5 minutes. Supernatant was aspirated and the cells
were re-suspended in 2 ml PBS. They were centrifuged again at 1500 rpm for
3-5 minutes; supernatant was aspirated; and the cells were re-suspended in
freezing medium. 1.5 ml of this was taken to 2 ml screw-capped cryotubes.
The cryotubes were placed at - 20°C for 1-2 hours, and taken to - 80°C for
3-7 days after that. They were then placed and stored in liquid nitrogen.
3.1.6 Serum Starvation Treatment
Serum-deficient media were prepared, according to the cell type, as either
DMEM or RPMI 1640 medium with 0.1% FBS instead of 10% FBS. The
other additives in the media that were listed in Section 3.2 did not change.
Serum starvation experiments were done for each of the 10 cell lines twice,
at different times. (1st batch=set1-2, 2nd batch=set3-4).
For serum starvation experiments, 4 x T75 flasks were taken and 10 ml com-
plete growth medium, specific to the particular cell type, was added to each.
3 x 106 cells were seeded to each T75 flask. The cells were incubated with
complete medium for 24 hours. After 24 hours, the medium was aspirated
and the cells were washed with PBS. 13 ml of 10% FBS medium was added
to 2 of the T75 flasks, and 13 ml of 0.1% FBS medium was added to the
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other 2 flasks. The cells were incubated for 48 hours.
3.1.7 β-Estradiol (E2) Treatment
For E2 treatment, the growth medium of the cells were changed to phenol
red-free Dulbecco’s MEM (F0475) (Biochrom AG, Berlin, Germany) with
5% charcoal/dextran-treated FBS (SH30068.02) (Hyclone, Logan, USA), 1%
penicillin/streptomycin solution and 1% non-essential amino acids. To iden-
tify the effects of estrogen on breast cancer cell lines, β-Estradiol (E2758)
(Sigma Aldrich, Missouri,USA) was used as estrogen substrate.
E2 stock solution was prepared by dissolving 27.238 mg E2 in 50 ml 100%
EtOH (32221) (Sigma Aldrich, Missouri, USA) so that the final concentra-
tion of the stock solution was 2 mM. The stock solution was filtered and
aliquoted to be stored in -20°C.
Final E2 treatment concentrations were 30 nM and 100 nM. For 30 mM final
concentration, 0.75µl of 2 mM stock solution was added to 50 ml phenol
red-free DMEM with 5% charcoal/dextran-treated FBS. For 100 mM final
concentration, 2.5 µl of 2 mM stock solution was added to 50 ml phenol red-
free DMEM with 5% charcoal/dextran-treated FBS.
The medium for 100nM E2 control group was prepared by adding 2.5 µl
100% EtOH to 50 ml phenol red-free DMEM with 5% charcoal/dextran-
treated FBS.
MCF7 cells were counted and 12 x T75 flasks were seeded with 1 x 106 cells.
They were incubated with regular 10% DMEM growth medium (with phe-
nol red) for 24 hours. After 24 hours, the media of the cells were changed
to phenol red-free DMEM with 5% charcoal dextran-treated FBS. The cells
were incubated with this medium for 72 hours. 72 hours later, the media was
changed to phenol red-free DMEM with 0.1% charcoal/dextran-treated FBS
(the rest of the additives from the 5% medium were not changed) in order to
synchronize the cell cycles of the cells to be able to properly assess the effect
of E2 treatment.
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After 24 hours, the 0.1% FBS medium was aspirated. 12 ml of media was
added to each flask, with four of them being the control medium, 4 of them
being 30 mM E2 treatment medium and 4 of them being 100 nM E2 treat-
ment medium. After 12 hours, 2 of the controls, 2 of the 30 nM treatments
and 2 of the 100 nM treatments were collected as pellets. The rest were
collected after 24 hours.
3.1.8 MTT Assay
MTT assay was done for all of the cell lines, in order to assess the effect
of serum starvation treatment on proliferation of breast cancer cell lines.
Vybrant® MTT Cell Proliferation Assay Kit (V13154) (Molecular Probes,
Oregon, USA).
12 mM MTT stock solution was prepared by dissolving 5 mg MTT in 1 ml
sterile PBS and stored at +4°C. SDS solution was prepared by dissolving 1
g SDS in 10 ml, 0.01 M HCl.
For MTT assay, 96-well plates (Greiner Bio One, Frickenhausen, Germany)
were used. 150 µl of 10% growth medium per well was added according to
the cell type. 12 wells were filled for each cell line and 5000 cells per well
were seeded. The cells were incubated at 37°C for 24 hours. After 24 hours,
the media in the wells were discarded by using a micropippette rather than
aspirating the medium with glass pasteurs. Then the plate was inverted to
get rid of the remaining medium. The wells were washed with 80-100 µl PBS;
PBS was, again, discarded by a micropippette; and the plate was inverted to
get rid of the remaining PBS. For each cell line, 150 µl of 10% medium was
added to 6 wells and 150 µl of 0.1% medium was added to 6 wells. The cells
were incubated at 37°C for 48 hours. After 48 hours, the media in the wells
were removed by a micropippette and the plate was inverted to get rid of the
remaining media. 100 µl fresh medium was added to the wells (10% medium
was used for the control groups and 0.1% medium was used for the serum
starvation treatment groups). For negative control, 100 µl of 10% medium
was added to 6 wells. 10 µl of the 12 mM MTT stock solution was added to
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each well and carefully mixed. The plates were incubated at 37°C for 4 hours.
After 4 hours, 100 µl of SDS-HCl solution was added to each well and the
plates were incubated at 37°for 12-18 hours. After the final incubation, each
sample was mixed again, and absorbance was read at 570 nm with µQuant
spectrophotometer (BioTek Instruments, Vermont, USA).
3.2 Gene Expression Analyses
3.2.1 Total RNA Isolation
At the end of serum starvation and β-Estradiol treatments, pellets of cells
were collected by aspirating the medium, washing the flasks with PBS and
trypsinizing them. 7-8 ml of media was added to collect the trypsinized cells
and the cells were centrifuged at 1500 rpm for 5 minutes. The supernatant
was aspirated and the cells were re-suspended in 1-2 ml PBS. They were
centrifuged at 1500 rpm for 5 minutes and the supernatant was aspirated.
The pellets were stored at -80°C until RNA isolation.
Before total RNA isolation, the cell pellets were taken from -80°C and were
thawed on ice. Then they were lysed completely with 1 ml TRIzol Reagent
(15596-026) (Life Technologies, California, USA). The lysates were taken to
1.5 ml tubes and 200 µl of chloroform was added to each tube. The tubes
were shaken vigorously for 10-15 seconds until they homogenized and they
were left to incubate for 3-5 minutes at room temperature. The tubes were
centrifuged at 13.200 rpm for 17 minutes at +4°C. After the centrifugation,
a clear phase can be seen. 500 µl of the clear phase were taken to new 1.5 ml
tubes and 500 µl isopropanol was added to each tube in order to precipitate
total RNA pellet. The tubes were gently inverted for a couple of times and
they were left to incubate at room temperature for 10 minutes. They were
then centrifuged at 13.200 rpm for 12 minutes at +4°C. The supernatant was
discarded, the pellet was washed with 1 ml 75% EtOH and centrifuged at
8000 rpm for 8 minutes at +4°C. The supernatant was discarded, 1 ml 100%
EtOH was added and the tubes were centrifuged again at 8000 rpm for 8
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minutes at +4°C. The supernatant was discarded and the pellets were left
under laminar flow to air dry.
After the pellets dried, they were dissolved in 30-40 µl Hypure Molecular Biol-
ogy Grade water (SH30538.03) (Hyclone, Logan, USA). The measurements of
the samples were taken with NanoDrop® ND-1000 spectrophotometer (Nan-
oDrop Technologies, USA). The RNA samples were stored at -80°C.
3.2.2 cDNA Synthesis
Isolated total RNA was used in cDNA synthesis. cDNA synthesis was done
with RevertAid First Strand cDNA Synthesis Kit (K1621) (Thermo Fisher
Scientific, Massachusetts, USA) according to the manufacturer’s protocol. 1
µg (for serum starvation set3-4) - 1.5 µg (for serum starvation set1-2) total
RNA was taken to 0.2 ml tubes. 1 µl oligo(dT) primer was added and the
mixture was completed to 12 µl total volume by adding nuclease-free water.
Other reagents were added (4 µl of 5x Reaction Buffer, 1 µl of RiboLock
RNase Inhibitor, 2 µl of 10 mM dNTP Mix, 1 µl of RevertAid M-MuLV
Reverse Transcriptase; in that order) to complete the total volume at 20 µl.
The tubes were incubated at 42°C for 60 min, followed by 5 minutes at 70°C
to terminate the reaction. They were stored at - 20°C.
3.2.3 Oligonucleotides
Primers that were used in this study are listed in Table 3.2.
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Table 3.2: Primer sequences and their product sizes.
Gene Sequence Product Size
ANLN Forward 5’-TAAAGCAGGTGATTGTTCGG-3’ 180 bpReverse 5’-GTTCTTCATCAACACAGCAG-3’
CHRNA5_W* Forward 5’-TTAAGATGGAACCCTGATGACTATG-3’ MultipleReverse 5’-ATTGTTGGATCTCTTGGGCTTTTT-3’
CHRNA5_All Forward 5’-AGATGGAACCCTGATGACTATGGT-3’ 104 bpReverse 5’-AAACGTCCATCTGCATTATCAAAC-3’
CHRNA5_200 Forward 5’-CATCAGGTGTTGAAGATTGGAAAT-3’ 101 bpReverse 5’-AAAAAGCCCAAGAGATCCAACAAT-3’
CHRNA5_1000 Forward 5’-GGAAACTGAGAGTGGTAGTGGA-3’ 122 bpReverse 5’-CTTCAACAACCTCACGGACA-3’
CHRNA5_iso2† Forward 5’-TGGAGAATGGGAGATTGTGAGTGCA-3’ 78 bpReverse 5’-CCAATCTTCAACAACCAGCAACAGC-3’
CHRNA5_iso3† Forward 5’-TGGAGAATGGGAGATTGTGAGTGCA-3’ 78 bpReverse 5’-CCAATCTTCAACAACGGATACCAGC-3’
PS2‡ Forward 5’-CCATGGAGAACAAGGTGATCTGC-3’ 208 bpReverse 5’-TTAGGATAGAAGCACCAGGGGAC-3’
SDHAº Forward 5’-TGGGAACAAGAGGGCATCTG-3’ 86 bpReverse 5’-CCACCACTGCATCAAATTCATG-3’
TPT1 Forward 5’-GATCGCGGACGGGTTGT-3’ 100 bpReverse 5’-TTCAGCGGAGGCATTTCC-3’
* Adapted from Warzecha et al., 200973
† Adapted from Falvella et al., 201343
‡Adapted from Alotaibi et al., 200674
ºAdapted from Gur-Dedeoglu et al., 200975
3.2.4 Polymerase Chain Reaction
Polymerase Chain Reactions were done using OneTaq Quick-Load Master
Mix (M0486L) (New England Biolabs, Massachusetts, USA) after optimizing
manufacturer’s protocol. The prepared PCRs and their reaction conditions
are listed in Table 3.3 and Table 3.4, respectively.
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Table 3.3: PCR reagents and their volumes.
PCR Reaction Volume
2x OneTaq QuickLoad Master Mix 12.5 µl
Forward primer (10pmol) 0.5 µl
Reverse primer (10pmol) 0.5 µl
cDNA 1 µl
DNase/RNase-free water 9.5 µl
Total 25 µl
Table 3.4: PCR conditions for specific primers.
PCR Steps CHRNA5_W, CHRNA5_All, SDHA,CHRNA5_200 CHRNA5_1000 TPT1
Initial Denaturation 95°C, 5’ 94°C, 5’ 94°C, 5’
Denaturation 95°C, 30” 95°C, 30” 95°C, 30”
Annealing 60°C, 90” 60°C, 30” 58°C, 30”
Extension 72°C, 90” 72°C, 30” 72°C, 30”
Number of cycles 35 40 40
Final Extension 68°C, 10’ 72°C, 5’ 72°C, 5’
’ denotes minutes, ” denotes seconds
3.2.5 Agarose Gel Electrophoresis
2% agarose gels were prepared by adding agarose to 1x TAE buffer. 1mg/ml
ethidium bromide solution was added. After the gel polymerized, the wells
were loaded with 10-12 µl PCR product. 4-5 µl GeneRuler 100bp DNA ladder
(SM0241) (Thermo Scientific, Waltham, Massachusetts, USA) was used.
3.2.6 Quantitative Real Time-Polymerase Chain Re-
action (qPCR)
qPCR was done using LightCycler® 480 SYBR Green I Master (04887352001)
(Roche Applied Science, Germany) after optimizing the manufacturer’s pro-
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tocol. Every sample in the plates, including negative controls, were done in
duplicates.
LightCycler® 480 PCR Instrument (Roche Applied Science, Germany) was
used as the PCRmachine and LightCycler® 480 Multiwell Plate 96 (04729692001)
(Roche Applied Sciences, Germany) was used as plate in these reactions.
The prepared PCRs and their reaction conditions are listed in Table 3.5 and
Table 3.6, respectively. Same conditions were used for each of the qPCR
primers.
Table 3.5: qPCR reagents and their volumes.
PCR Reaction Volume
LightCycler 480 SYBR Green I Master 5 µl
Forward primer (10pmol) 1 µl
Reverse primer (10pmol) 1 µl
cDNA 2 µl
DNase/RNase-free water 1 µl
Total 10 µl
Table 3.6: qPCR conditions.
PCR Steps
Initial Denaturation 95°C, 5’
Denaturation 95°C, 10”
Annealing 58°C, 20”
Extension 72°C, 20”
Number of cycles 45
Acquisition
95°C, 5”
55°C, 1’
95°C, Continuous acquisition
Final Extension 40°C, 10”
’ denotes minutes, ” denotes seconds
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3.3 Analyses of Serum-Starvation qPCR Re-
sults
The results of the qPCR experiments were taken as Cts (Cq) calculated by
the 2nd derivative method.
3.3.1 Detection of qPCR Outliers with Matlab
Several outlier detection methods exist in the literature for analyzing microar-
ray data and other datasets.66,76 It is important that the outlier detection is
done carefully, so that only the extreme outliers are removed.77 If both of the
technical duplicates of a sample as detected as outliers, they are not removed
since this variation may pertain to the biological characteristics of the partic-
ular sample. Outliers that result from technical problems can occur because
of inhibition of PCR reactions and these can be detected by using a PCR
kinetics approach.78 As well as using manual detection, researchers have
also used existing softwares for the detection of unusually variable points in
technical triplicates.79,80 Standard deviations were also used as parameters
within a study group with given restrictions (e.g. no more than a certain
number of group members were excluded).80 Visual inspection of boxplots of
the data, followed by a statistical analysis was also suggested as a method for
outlier detection.66 According to this method, data points that fall outside
the range of the box and whisker plots can be considered potential outliers.
Using Grubb’s test has also been suggested for outlier detection and exclu-
sion for qPCR data.66 In this test, whether a data point belongs to the
population is tested based on the difference between the mean and the most
extreme value upon normalization with the standard deviation. This provides
a statistical measure of how much suspected outlier deviates from normal dis-
tribution.81
In order to analyze a more uniform data and minimize experimental errors,
in the present study, we used a method that is similar to that of Burns et
al. (2005).66 Existing functions for outlier detection based on IQR in Mat-
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lab® (version: 2008b) were used to write a code (Appendix A Table 7.1) in
order to detect the outlier Ct values of qPCRs. It was run for starvation
set1-2 and starvation set3-4 separately. The boxplots themselves represent
the 25% to 75% of the data, and the whiskers have a default length of 1.5.
This corresponds to approximately 99.3 coverage, assuming the data is nor-
mally distributed. The working principle for the outlier detection code is as
follows:
• It takes an xls file that contains both of the qPCR runs for a particular
gene and a batch as input.
• It groups Ct values corresponding to each cell line and draws a boxplot
(including both 10% and 0.1% values), separately for each cell line.
• The boxplot shows whether or not there are any outliers in Ct values
for each cell line by marking it with a + sign.
• If there are any outliers, it detects the index of the outlier and replace
that Ct value with ‘NaN’.
After the replacement is done, the newly generated files are manually checked
and if there are any samples in which both of the duplicates are flagged, these
are replaced with their original Ct values.
3.3.2 Geometric Mean of Reference Genes
TPT1 and SDHA were chosen as reference genes and two runs of each was
done for each set. Reference gene selection and the number of reference genes
to be used are among important aspects of qPCR data normalization. It is
assumed that RNA is converted to cDNA with equal efficiency and amount
for each sample. A deviation from this expectation may result in sample
variation attributable to either technical or biological issues and it is difficult
to address which one is in effect. One solution to overcome the variations
in RNA amounts in a qPCR run is the use of multiple reference genes for
normalization.63 Another issue with the use of reference genes is deciding
which gene is appropriate for a given condition. Recent studies have shown
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that there is no uniform reference gene that can be used in all studies.79
We addressed whether TPT1 and SDHA, two commonly used reference genes,
can be used to assess the amounts of RNA preparation in our serum starva-
tion experiments. For this, we looked for Affymetrix microarray experiments
that were conducted on serum starved samples in the GEO database. For
each dataset, TPT1 and SDHA probesets were analyzed using GEO2R util-
ity of the GEO database. Table 3.7 shows the names of the GSE datasets
analyzed for TPT1 and SDHA probesets. Figures 7.1 to 7.6 in Appendix B
show the expression values of TPT1 and SDHA in the control (no starvation)
and treatment (serum starved) groups.
Table 3.7: GSE datasets that were analyzed for TPT1 and SDHA probesets.
GEO Datasets* SDHA probeset TPT1 probeset References
GSE21648 201093_x_at 212869_x_at
Enoch S, Peake MA, Wall I, Davies L et al.
’Young’ oral fibroblasts are geno/phenotypically
distinct. J Dent Res 2010 Dec;89(12):1407-13.
PMID: 21098492
GSE31040 201093_x_at 212869_x_at
Matarrese P, Tinari A, Ascione B, Gambardella
L et al. Survival features of EBV-stabilized cells
from centenarians: morpho-functional and
transcriptomic analyses. Age (Dordr) 2012
Dec;34(6):1341-59. PMID: 21904824
GSE1692 201093_x_at 216520_s_at
Cam H, Balciunaite E, Blais A, Spektor A et al.
A common set of gene regulatory networks links
metabolism and growth inhibition. Mol Cell 2004
Nov 5;16(3):399-411. PMID: 15525513
GSE8597 201093_x_at 216520_s_at
Bourdeau V, Deschênes J, Laperrière D, Aid M
et al. Mechanisms of primary and secondary
estrogen target gene regulation in breast cancer
cells. Nucleic Acids Res 2008 Jan;36(1):76-93.
PMID: 17986456
* NCBI GEO: archive for functional genomics data sets. 10 years on. Tanya Barrett, Dennis B. Troup,
Stephen E. Wilhite, Pierre Ledoux, Carlos Evangelista, Irene F. Kim, Maxim Tomashevsky, Kimberly A.
Marshall, Katherine H. Phillippy, Patti M. Sherman, Rolf N. Muertter, Michelle Holko, Oluwabukunmi
Ayanbule, Andrey Yefanov, Alexandra Soboleva. Nucleic Acids Res. 2011 January; 39(Database issue):
D1005?D1010. Published online 2010 November 20. doi: 10.1093/nar/gkq1184.
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Based on these microarray analyses, TPT1 and SDHA seem to be relatively
stable reference genes. A code was written in Matlab to get geometric aver-
ages of the Ct values in order to obtain a composite reference Ct value. The
code takes the average Ct values of the duplicates in each run, then average
Ct of the samples between runs. This was done separately for TPT1 and
SDHA and for set1-2 and set3-4. After the generation of these two reference
files for each set, geometric means of the Ct values for TPT1 and SDHA were
calculated for each set and written on an xls file as an output. This newly
generated file was used as reference in further analysis. The code used for
this can be seen in Appendix A Table 7.2
A similar test was performed to see whether TPT1 and SDHA expressions
change under β-estradiol stimulation, using a benchmark dataset from GEO
(GSE8567). This also indicated that these two reference genes were stable
between groups and did not exhibit large fold differences. The expression val-
ues of TPT1 and SDHA in control (no treatment) and treatment (β-estradiol
treatment) groups can be seen in Figures 7.7 and 7.8 in Appendix B.
3.3.3 Statistical Analysis of qPCR Data
There are several methods for relative assessment of expression values ob-
tained from qPCR data. Among these methods, ∆∆Ct or ∆Ct method, with
or without efficiency correction, is the most commonly used.82 This requires
the target gene expression to be subtracted from the reference gene expres-
sion for each of the samples. Then, if necessary, common reference samples
are used to obtain a relative fold change value for each sample (∆∆Ct). Re-
cent studies also advocate the use of log values rather than simple fold change
for statistical accuracy purposes. Statistical analysis of qPCR data has been
reviewed, focusing on comparisons of different statistical tests (multiple re-
gression analysis, Analysis of Covariance (ANCOVA) and t-test).83 They
emphasized that equal amplification efficiencies were more important when
using the ∆∆Ct method. Multiple regression analysis enables one to incor-
porate different effects, including treatment and gene effects, into the model,
as well as any interactions between them. ANCOVA allows the usage of a
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covariate, which makes it possible to test the difference between the control
and the treatment groups after the effect of reference genes is taken away,
thus standardizing the treatment effects from different batches. ANCOVA
can be a very effective method to adjust for batch effects, especially when
multiple qPCR runs of the same control and treatment groups are included in
the analysis. It also permits detection of slope differences between treatment
groups as well as provides a significance value for each group for testing the
intercept. All of these methods, however, depends on the selection of true
reference genes whose expressions are relatively stable among samples and
experimental groups.
In our experimental design for serum starvation, two sets (set1-2 and set3-
4) of control-treatment experiments were performed at different times with
different batches of the same cell lines. In each set, a total of four replicates
from two separate qPCR runs were included for each sample (n=4 per group,
2 groups). We have chosen an approach that sequentially incorporates:
• Detection of outliers that can be attributed to technical errors,
• Averaging of duplicates for a sample, followed by averaging the values
of each sample from different runs,
• Geometric averaging of reference genes for each batch separately.
For a gene of interest (2 references and 2 target genes), duplicate values were
averaged for each individual. For the reference genes this was done before
obtaining a geometric average set-wise. The batches (set1-2 and set3-4) were
then combined for ANCOVA, in which the geometric average of TPT1 and
SDHA was used as the covariate to test for the differences in expression of
CHRNA5 isoforms between cell lines for 10% FBS and 0.1% FBS treated
cells separately and between serum starvation and control groups for each
cell line separately.
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3.3.3.1 Pearson Correlation Between 200bp and 1000bp CHRNA5
Isoforms
Scatter graphs for 200bp CHRNA5 and 1000bp CHRNA5 isoforms were plot-
ted using Matlab®. To check for correlation between these two isoforms,
Pearson correlation values were calculated, with r values and their associ-
ated p-values under serum and no serum conditions.
3.3.3.2 ANCOVA
a) For all cell lines
A Matlab code was written to analyze the expression differences of CHRNA5
isoforms between cell lines, normalized to the geometric mean of the two
reference genes, using ANCOVA (aoctool). This was done separately for
10% FBS treated cell lines and 0.1% FBs treated cell lines.
The code written for ANCOVA for all cell lines can be seen in Appendix A
Table 7.3.
b) For each cell line, for the effect of serum starvation
In order to test whether serum starvation affected the mean expression values
of CHRNA5 isoforms between control and treatment groups, ANCOVA was
used. This also allowed us to get rid of the batch effect that can result from
using different batches of cell lines, since it standardizes over the geometric
mean of TPT1 and SDHA across all sets at the same time. This model
assumes that there is a linear relationship, if any, between the reference gene
and target gene. The Matlab code written for ANCOVA for separate cell lines
can be seen in Appendix A Table 7.4. In the code, a covariate description
file, which includes the indices of cell lines, is used. Other files that are called
from the code are ref12 or ref34 containing the geometric means of references
for sets; and trg12 or trg34 containing the arithmetic means of targets (either
200bp variant of CHRNA5 or 1000bp variant of CHRNA5).
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3.4 Analyses of β-Estradiol Treatment Results
For the analysis of β-Estradiol(E2) treatment, no outlier detection was per-
formed since it is a smaller dataset and number of technical replicates is two.
Geometric means of the two reference genes TPT1 and SDHA were, again,
taken (after taking the averages of duplicates). The expressions of the refer-
ence genes TPT1 and SDHA were checked in GEO database using GSE8597
dataset, which includes β-estradiol treatment. Analysis indicated that these
two genes were, again, relatively stable in the presence of estrogen as they
were under starvation conditions. Two-way ANOVAs were performed in R
(www.bioconductor.org) on logarithmically transformed fold changes (∆∆Ct
with reference genes) that were calculated using Microsoft Excel. ∆∆Ct val-
ues were calculated standardized to the average value of time specific control
group for 12h and 24h, separately.
3.4.1 Two-way Anova analysis with R
Our experimental design involves two factors: a dose effect (0 and 100nM)
and a time effect (12h and 24h). This calls for a statistical test in which
all sources of variation, including the interaction between the two, could
be accounted for at the same time to increase statistical power. In order to
detect the effects of E2, a two-way ANOVA analysis was done for each primer
that was used, using ‘anova(lm())’function in R. csv files were generated for
each primer, including information about the dose and time of E2 treatment
and the fold changes observed, compared to the controls. Boxplots of changes
in expression values were drawn, showing the differences between the means.
Table 3.8 shows an example of these csv files.
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Table 3.8: An example of csv files used in two-way ANOVA analysis for E2-
treatment data.
200bp group dose time
0.815 0nm12 0 12
-0.815 0nm12 0 12
3.09 100nm12 100 12
0.22 100nm12 100 12
-0.65 0nm24 0 24
0.65 0nm24 0 24
2.765 100nm24 100 24
3.185 100nm24 100 24
3.4.2 ANCOVA of CHRNA5 expression
ANCOVA was done in Matlab in order to se if there is a difference in the
trends of response to E2 between 12h and 24h. ANCOVA gives two p-values,
one for the significance of dose and another for the significance of time.
3.4.3 Saturation Analysis of E2 Treatment
In order to identify the concentration of E2 that is required to reach a satu-
ration level for the increase in CHRNA5 expressions, additional data points
of 30nM E2 treated samples were used (both for 12h and 24h). These 30nM
treated samples do not have their own controls but they will give us an idea
about the E2 concentration needed for our future experiments. Logarithmi-
cally converted fold changes of CHRNA5 isoforms in response to 12h and 24h
of 0nM, 30nM and 100nM E2 treatment were used to create scatter graphs
with Microsoft Excel.
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3.5 General Solutions
• 50x Tris-acetic-EDTA (TAE): 242 g Tris base and 18.6 g EDTA
were dissolved in ddH2O. 57.1 ml glacial acetic acid was added and the
volume was completed to 1 lt.
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Chapter 4
RESULTS
4.1 Expression of CHRNA5 Isoforms in Cell
Lines
To determine the presence of splice variants of CHRNA5 in breast cancer
cell lines, primers that amplified all of the expected variants were used
(CHRNA5_W in Table 3.2) for RT-PCR. TPT1 was used as a reference
gene. Figure 4.1 shows that there are at least 4 isoforms of CHRNA5 using
this primer pair in our breast cancer panel consisting of 10 cell lines and each
of these isoforms are differentially expressed between different breast cancer
cell lines. According to the results in Figure 4.1, we decided to focus on two
of the splice variants of CHRNA5, namely the 200bp variant and the 1000bp
variant. These isoforms have been cut from the gel, cloned and sequenced to
verify that they belonged to CHRNA5 (data not shown). SDHA was used as
the reference gene and expression of these two variants and another primer
that amplifies all of the variant of CHRNA5 was determined in our panel. 2
sets for each cell line was used. Figure 4.2 shows that all the variants investi-
gated can be amplified in all of the cell lines, using sequence specific primers
(Table 3.2). Differences between cell lines could not be identified via regular
RT-PCR, which made use of qPCR a necessity.
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Figure 4.2: Expression of different CHRNA5 variants and SDHA across two sets
of each of the 10 breast cancer cell lines.
4.2 Effects of Serum Starvation Treatment
4.2.1 Effects of Serum Starvation on Cell Proliferation
and Viability
To investigate the effects of serum starvation treatment on cell viability and
proliferation, MTT assay was done for each of the 10 cell lines. MTT assay
is a colorimetric assay that measures the cell viability by the presence of
enzymes in viable cells that are able to process MTT to formazan, giving a
purple color. The absorbance value is proportional to cell viability. Figures
4.3 to 4.12 show the MTT assay results for the cell lines in Table 1.3. Data
were analyzed using unpaired, equal variance t-tests for each cell line between
the control and treatment groups using Microsoft Excel.
The results show a significant decrease in cell viability and proliferation for 7
of the 10 cell lines under study. For ZR-75-1, MDAMB 453, BT-20, MDAMB
468, MDAMB 231 cell lines; p < 0.0001, for MDAMB 361 cell line; p < 0.005,
for MDA MB 157 cell line; p < 0.05 were observed. The remaining cell lines
(MCF7, T47D, HCC 1937) did not exhibit a significant difference in their
viability or proliferation rates in response to serum starvation treatment.
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Table 4.1: MTT results for all cell lines.
Cell Line Cnt. Abs. Cnt. StD. Strv. Abs. Strv. StD. p-value
MCF7 0.492 0.036 0.417 0.092 0.095851667
T47D 0.264 0.056 0.253 0.045 0.733955993
ZR-75-1 0.709 0.026 0.417 0.038 0.0000000280
MDA MB 361 0.182 0.046 0.101 0.025 0.003702561
MDA MB 453 0.390 0.047 0.130 0.025 0.0000002938
BT-20 0.838 0.091 0.383 0.035 0.0000004705
HCC 1937 0.188 0.035 0.182 0.040 0.788276551
MDA MB 468 0.645 0.052 0.292 0.047 0.0000002363
MDA MB 231 0.523 0.039 0.147 0.028 0.0000000030
MDA MB 157 0.217 0.060 0.141 0.026 0.016540839
Cnt. Abs.: absorbance values of control groups
Cnt. StD.: standard deviation of control groups
Strv. Abs.: absorbance values of starvation groups
Strv. StD.: standard deviation of starvation groups
Table 4.2: Fold changes of MTT absorbance values between 10% and 0.1% FBS
treated breast cancer cell lines.
Cell Line Fold Change log.fc
ZR-75-1 0.588152327 -0.765738244
T47D 0.958333333 -0.061400545
HCC 1937 0.968085106 -0.046794211
MDA MB 231 0.281070746 -1.830994791
MCF7 0.847560976 -0.238610932
MDA MB 157 0.649769585 -0.62199988
MDA MB 453 0.333333333 -1.584962501
MDA MB 361 0.554945055 -0.849583157
MDA MB 468 0.452713178 -1.143330791
BT-20 0.457040573 -1.129605852
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Figure 4.3: MTT assay results for MCF7 cells. Y axis shows cell viability and x
axis shows treatment FBS.
Figure 4.4: MTT assay results for T47D cells. Y axis shows cell viability and x
axis shows treatment FBS.
Figure 4.5: MTT assay results for ZR-75-1 cells. Y axis shows cell viability and
x axis shows treatment FBS. **, p<0.0001
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Figure 4.6: MTT assay results for MDA MB 361 cells. Y axis shows cell viability
and x axis shows treatment FBS. *, p<0.005
Figure 4.7: MTT assay results for MDA MB 453 cells. Y axis shows cell viability
and x axis shows treatment FBS. **, p<0.0001
Figure 4.8: MTT assay results for BT-20 cells. Y axis shows cell viability and x
axis shows treatment FBS. **, p<0.0001
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Figure 4.9: MTT assay results for HCC 1937 cells. Y axis shows cell viability
and x axis shows treatment FBS.
Figure 4.10: MTT assay results for MDA MB 468 cells. Y axis shows cell via-
bility and x axis shows treatment FBS. **, p<0.0001
Figure 4.11: MTT assay results for MDA MB 231 cells. Y axis shows cell via-
bility and x axis shows treatment FBS. **, p<0.0001
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Figure 4.12: MTT assay results for MDA MB 157 cells. Y axis shows cell via-
bility and x axis shows treatment FBS. +, p<0.05
4.2.2 Effects of Serum Starvation on CHRNA5 Variant
Expression
4.2.2.1 Outlier Detection in qPCR data
In order to do a more accurate analysis of the qPCR data, potential outlier
values due to possible experimental errors in single wells were identified and
excluded from the analysis as explained in the Materials & Methods section.
A Matlab code was used for the automation of this procedure (see Appendix
A Table 7.1). Boxplots of Ct values for each cell line were drawn for each
gene (Figures 4.13 to 4.16). Box plots identify the 52%-75% of the data dis-
tribution and whiskers cover about 99%. Potential outliers are marked with
a ‘+’ sign.
Figure 4.13 shows the outlier analysis for TPT1. In set1-2, two potential
outlier values were detected (1 in MDA MB 231 cells and 1 in MDA MB 453
cells). In set3-4 five potential outlier values were detected (1 in MDA MB
231 cells, 1 in MDA MB 157 cells, 1 in MDA MB 453 cells and 2 in MDA
MB 468 cells).
Figure 4.14 shows the outlier analysis for SDHA. In set1-2, two potential
outlier values were detected (both in MDA MB 231 cells). In set3-4, eight
potential outlier values were detected (4 in MDA MB 231 cells, 1 in MCF7
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cells, 2 in MDA MB 157 cells and 1 in BT-20 cells).
Figure 4.15 shows the outlier analysis for 200bp variant of CHRNA5. In
set1-2, eleven potential outlier values were detected (2 in ZR-75-1 cells, 1 in
MCF7 cells, 3 in MDA MB 157 cells, 1 in MDA MB 453 cells, 2 in MDA
MB 361 cells and 2 in BT-20 cells). In set3-4, 2 potential outlier values were
detected (1 in MDA MB 453 cells, 1 in MDA MB 361 cells).
Figure 4.16 shows the outlier analysis for 1000bp variant of CHRNA5. In
set1-2, seven potential outlier values were detected (3 in ZR-75-1 cells, 2 in
MCF7 cells, 1 in MDA MB 361 cells and 1 in MDA MB 468 cells). In set3-4,
eight potential outlier values were detected (1 in HCC 1938 cells, 1 in MDA
MB 231 cells, 1 in MCF7 cells, 1 in MDA MB 453 cells, 1 in MDA MB 361
cells, 2 in MDA MB 468 cells and 1 in BT-20 cells).
All of the detected potential outliers were replaced with ‘NaN’. After the
replacements were done, the data was manually checked. If there were cases
where both of the duplicates for a sample were replaced with ‘NaN’, both of
these values were left unreplaced. There were two such cases, both in SDHA
of set3-4, in which both of the duplicates in a sample from MDA MB 231
cells and a sample from MDA MB 157. Altogether, out of 1280 data points,
45 were detected as potential outliers using the boxplot method; and 41 of
them were replaced with ‘NaN’, corresponding to 3.2% of the data.
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Figure 4.13: Outlier analysis for TPT1.
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Figure 4.14: Outlier analysis for SDHA.
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Figure 4.15: Outlier analysis for 200bp CHRNA5.
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Figure 4.16: Outlier analysis for 1000bp CHRNA5.
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4.2.2.2 CHRNA5 variant expression in Cell Lines
Expression of 200bp and 1000bp CHRNA5 variants were compared in 10%
and 0.1% FBS treated cell lines by drawing scatter plots using their respective
∆Ct values. Figures 4.17 and 4.18 show the comparisons. Since we are using
∆Ct values as targetCt − referenceCt, higher ∆Ct values correspond to
lower mRNA expression.
In both 10% and 0.1% FBS treated cells, 200bp variant of CHRNA5 and
1000bp variant of CHRNA5 were correlated. 10% treated cells have an r
value (r; Pearson correlation coefficient) of 0.9221 and a p-value of 0 and the
0.1 % treated cells have an r value of 0.8859 and a p-value of 0. There is
a grouping of cell lines according to expressions of CHRNA5 variants and
this correlates with the molecular subtypes of cell lines. Based on ∆Ct
values, cell lines belonging to the HER2+ subtype, MDA MB 453 and MDA
MB 361, have the lowest expression (highest ∆Ct) of CHRNA5 variants,
while luminal cell lines MCF7, T47D and ZR-75-1 cell lines, together with
post-EMT basal cell lines MDA MB 231 and MDA MB 157, are grouped
in the middle. Basal type cell lines BT-20 and MDA MB 468 have the
highest expression of CHRNA5 variants, when considering expression of both
isoforms simultaneously. Figures 4.17 and 4.18 also indicate that there is
considerable batch effect, particularly in 0.1% FBS treatment, e.g., MDA
MB 468, MDA MB 361, T47D.
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Figure 4.17: 200bp and 1000bp CHRNA5 expression across 10% FBS treated
cell lines.
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Figure 4.18: 200bp and 1000bp CHRNA5 expression across 0.1% FBS treated
cell lines.
ANCOVA was done to investigate the statistical significance of the correla-
tion between 200bp and 1000bp CHRNA5 variants in 10% and 0.1% FBS
treated cells. Figure 4.19 shows the comparison.
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ANCOVA shows that expressions of 200bp and 1000bp CHRNA5 variants
do not differ significantly across all cell lines, both in 10% and 0.1% FBS
treated cells.
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Figure 4.19: ANCOVA of 200bp and 1000bp CHRNA5 variants in 10% and 0.1%
FBS treated cell lines. grp, serum treatment effect; eh, slope for
isoform comparison across expression. 0 (red) refers to 0.1% FBS
and 1 (blue) refers to 10% FBS treatment, respectively.
59
4.2.2.3 Comparison of CHRNA5 Variant Expression Between Cell
Lines
The panel of 10 breast cancer cell lines were compared with respect to their
expression of the 1000bp variant and the 200bp variant under different serum
supplement regimes. ANCOVA was used to obtain an estimate of relative
expression for each line associated with a specific p-value (Table 4.3. AN-
COVA was performed assuming parellel lines, i.e., all cell lines were related
with reference genes with a similar slope).
The higher the value, the lower the expression, since we used Ct values in
comparison. ANCOVA takes the reference gene expression (i.e. geometric
mean of TPT1 and SDHA) as a covariate and tests the mean differences
among cell lines. Parallel lines were assumed, considering the reference genes
will behave similarly for each cell line. ANCOVA produces two p-values, one
for the treatment effect and the other for the correlation of reference gene
expression with that of the target genes (i.e., 1000bp and 200bp CHRNA5
isoforms). A p-value of less than 0.05 was considered significant.
Figures 4.20 to 4.27 compare the expression values between cell lines. Both
in 10% FBS treated cells and 0.1% FBS treated cells, MDA MB 453 and
MDA MB 361 cells (HER2 positive subtype) have the lowest expression of
both variants.
The order of expression in the controls from the lowest to the highest for
200bp CHRNA5 is as follows: MDA MB 453; MDA MB 361; MDA MB 231;
ZR-75-1; MDA MB 157; T47D; MDA MB 468; BT-20; MCF7; HCC 1937.
The order of expression in the controls from the lowest to the highest for
1000bp CHRNA5 is as follows: MDA MB 453; MDA MB 361; MDA MB
231; ZR-75-1; MDA MB 157; HCC 1937; MCF7; T47D; MDA MB 468;
BT-20. Table 4.3 shows the p-values for each cell line.
60
Table 4.3: p-values of ANCOVA for all cell lines, pertaining to Figures 4.20-4.27.
200bp CHRNA5 1000bp CHRNA5
Cell Line 10% 0.1% 10% 0.1%
ZR-75-1 0.253 0.0449 0.4528 0.2224
T47D 0.0789 0.0102 0.0764 0.0482
HCC 1973 0.002 0.0054 0.2363 0.1502
MDA MB 231 0.1252 0.3445 0.2208 0.6094
MCF7 0.0066 0.0018 0.0704 0.0029
MDA MB 157 0.3727 0.1153 0.3169 0.9453
MDA MB 453 0 0 0 0
MDA MB 361 0.0002 0.0007 0.0002 0.002
MDA MB 468 0.0476 0.0294 0.0263 0.5945
BT-20 0.0185 0.1185 0.0001 0
ANCOVA also gives intercept values for each cell line that indicates where
the cell line expressions are located along the expression gradient of the tar-
get gene. Each intercept has a p-value reflecting whether that cell line is
statistically distinguishable from the others. The tables associated with each
gene under a given serum treatment show the sources of variation (cell line,
slope of the reference gene; and also the intercepts) (Figures 4.20 to 4.26).
Figure 4.20 shows the comparison for the expression of 200bp CHRNA5 vari-
ant in 10% FBS treated cell lines. 200bp CHRNA5 expression highly sig-
nificantly varies between cell lines, with Ct values ranging between 23 and
29, while the reference genes’ expression stays relatively unchanged, with Ct
values ranging from 17 to 19.5. The slope of the reference gene is also signif-
icant, suggesting that there might be an RNA quantification bias or a mild
variability of the reference genes among cell lines, due to individual sample
variability or batch effect.
Figure 4.22 shows the comparison for the expression of 200bp CHRNA5 vari-
ant in 0.1% FBS treated cell lines. 200bp expression has Ct values between
23 and 29, while reference Ct values are between 17 and 19.5. In 0.1% FBS
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treated cells, the correlation between 200bp CHRNA5 and reference genes
seem to disappear.
Figure 4.24 shows the comparison for the expression of 1000bp CHRNA5
variant in 10% FBS treared cell lines. 1000bp CHRNA5 expression varies
between cell lines, with Ct values ranging from 21 to 28, while the reference
genes’ expression stays relatively unchanged, with Ct values between 17 and
19.5. The slope of the reference gene is also significant here, suggesting that
there might, again, be an RNA quantification bias or a mild variability of
the reference genes among cell lines, due to individual sample variability or
batch effect.
Figure 4.26 shows the comparison for the expression of 1000bp CHRNA5
variant in 0.1% treated cell lines. 1000bp expression has Ct values between
21 and 28, while reference Ct values are between 17 and 19.5. Again, the
correlation between the 1000bp CHRNA5 variant and reference genes disap-
pears in 0.1% FBS treated cells.
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Figure 4.20: Comparison of 200bp CHRNA5 expression among brest cancer cell
lines grown with 10% FBS.
Figure 4.21: Probability values of 200bp CHRNA5 expression of breast cancer
cell lines grown in 10% FBS.
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Figure 4.22: Comparison of 200bp CHRNA5 expression among brest cancer cell
lines grown with 0.1% FBS.
Figure 4.23: Probability values of 200bp CHRNA5 expression of breast cancer
cell lines grown in 0.1% FBS.
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Figure 4.24: Comparison of 1000bp CHRNA5 expression among brest cancer cell
lines grown with 10% FBS.
Figure 4.25: Probability values of 1000bp CHRNA5 expression of breast cancer
cell lines grown in 10% FBS.
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Figure 4.26: Comparison of 1000bp CHRNA5 expression among brest cancer cell
lines grown with 0.1% FBS.
Figure 4.27: Probability values of 1000bp CHRNA5 expression of breast cancer
cell lines grown in 0.1% FBS.
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4.2.2.4 Comparison of CHRNA5 Variant Expression in Response
to Serum Starvation Treatment
ANCOVA was done in order to assess the effects of serum starvation treat-
ment in each cell line. ANCOVA gives a p-value for the significance of the
treatment, and a p-value for the slope of the correlation graph, which shows
whether there is a significant correlation between the target gene (either
200bp or 1000bp CHRNA5) and reference genes that might be due to indi-
vidual variability, experimental error and/or batch effect. Table 4.4 shows
the p-values of treatment, slope and intercept of each cell line for the expres-
sion of the 200bp variant of CHRNA5. A p-value below 0.05 is considered
significant. According to this cutoff, expression of 200bp CHRNA5 is sig-
nificantly altered in ZR-75-1 and MDA MB 157 cells with serum starvarion
treatment.
Table 4.4: ANCOVA results of each cell line for 200bp CHRNA5.
Cell Line p-value Slope(p) Intercept(p)
ZR-75-1 0.0132 0.0018 0
T47D 0.8867 0.5047 0.001
HCC 1937 0.1391 0.006 0.5296
MDA MB 231 0.7916 0.666 0.4971
MCF7 0.3319 0.698 0.0136
MDA MB 157 0.0314 0.163 0.8314
MDA MB 453 0.9816 0.6345 0.0092
MDA MB 361 0.9399 0.1006 0.0106
MDA MB 468 0.7359 0.3949 0.0303
BT-20 0.6386 0.1326 0.9266
Table 4.5 shows the p-values of treatment, slope and intercept of each cell
line for the expression of the 1000bp variant of CHRNA5. A p-value below
0.05 is considered significant. According to this cutoff, there seems to be no
significant change in the expression of 1000bp CHRNA5.
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Table 4.5: ANCOVA results of each cell line for 1000bp CHRNA5.
Cell Line p-value Slope(p) Intercept(p)
ZR-75-1 0.3723 0.0101 0.0003
T47D 0.3422 0.8694 0.0197
HCC 1937 0.0757 0.0075 0.3917
MDA MB 231 0.8936 0.7298 0.5129
MCF7 0.1276 0.9197 0.0059
MDA MB 157 0.1313 0.0465 0.4994
MDA MB 453 0.852 0.3404 0.03
MDA MB 361 0.8602 0.2299 0.0399
MDA MB 468 0.132 0.1247 0.0094
BT-20 0.7394 0.0094 0.9602
Figures 4.28 to 4.47 show ANCOVA graphs with p-values of treatment and
slope of each cell line, separately for 200bp isoform of CHRNA5 and 1000bp
isoform of CHRNA5.
68
Figure 4.28: ANCOVA for 200bp CHRNA5 expression in ZR-75-1 cell line. 0
(red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
Figure 4.29: ANCOVA for 1000bp CHRNA5 expression in ZR-75-1 cell line. 0
(red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
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Figure 4.30: ANCOVA for 200bp CHRNA5 expression in T47D cell line. 0 (red)
refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
Figure 4.31: ANCOVA for 1000bp CHRNA5 expression in T47D cell line. 0
(red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
70
Figure 4.32: ANCOVA for 200bp CHRNA5 expression in HCC 1937 cell line. 0
(red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
Figure 4.33: ANCOVA for 1000bp CHRNA5 expression in HCC 1937 cell line. 0
(red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
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Figure 4.34: ANCOVA for 200bp CHRNA5 expression in MDA MB 231 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
Figure 4.35: ANCOVA for 1000bp CHRNA5 expression in MDA MB 231 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
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Figure 4.36: ANCOVA for 200bp CHRNA5 expression in MCF7 cell line. 0
(red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
Figure 4.37: ANCOVA for 1000bp CHRNA5 expression in MCF7 cell line. 0
(red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
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Figure 4.38: ANCOVA for 200bp CHRNA5 expression in MDA MB 157 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
Figure 4.39: ANCOVA for 1000bp CHRNA5 expression in MDA MB 157 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
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Figure 4.40: ANCOVA for 200bp CHRNA5 expression in MDA MB 453 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
Figure 4.41: ANCOVA for 1000bp CHRNA5 expression in MDA MB 453 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
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Figure 4.42: ANCOVA for 200bp CHRNA5 expression in MDA MB 361 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
Figure 4.43: ANCOVA for 1000bp CHRNA5 expression in MDA MB 361 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
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Figure 4.44: ANCOVA for 200bp CHRNA5 expression in MDA MB 468 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
Figure 4.45: ANCOVA for 1000bp CHRNA5 expression in MDA MB 468 cell
line. 0 (red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS
treatment, respectively. sources of variation: g, treatment group; f,
covariate.
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Figure 4.46: ANCOVA for 200bp CHRNA5 expression in BT-20 cell line. 0
(red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
Figure 4.47: ANCOVA for 1000bp CHRNA5 expression in BT-20 cell line. 0
(red) refers to 0.1% FBS and 1 (blue) refers to 10% FBS treatment,
respectively. sources of variation: g, treatment group; f, covariate.
78
4.3 Effects of E2 treatment
4.3.1 Two-way Anova According to Dose and Time
In order to assess the effects of E2 treatment, two-way ANOVA was used in
R, taking the log fold change between the target gene and geometric mean of
TPT1 and SDHA (∆Ct) as input. Figures 4.48 to 4.54 show ANOVA tables
and boxplots for the seven genes/primers investigated.
Estrogen may act directly or indirectly to induce or repress expression of
its target genes. Previous microarray experiments have shown that in the
presence of cycloheximide, where new protein synthesis is inhibited, most of
the E2 responsive genes are primary targets and this includes pS2 gene.19,74,84
A secondary target of E2 is anilin (ANLN), whose expression is negatively
correlated with survival.84
Tables 4.6 and 4.7 shows fold changes in PS2 expression in response to E2
treatment in MCF7 cells and their significance values according to dose, time
and dose:time. Results indicate that PS2 expression significantly increases
in response to E2 treatment in time and dose:time (p<0.01) tests. Figure
4.48 shows the boxplot of the results.
Table 4.6: Log2-fold changes of PS2 in response to E2 treatment.
ps2 group dose time
1 -1.9213997 0nm12 0 12
2 1.9213997 0nm12 0 12
3 -2.5747162 100nm12 100 12
4 -6.7655195 100nm12 100 12
5 -0.5830048 0nm24 0 24
6 0.5830048 0nm24 0 24
7 9.5587232 100nm24 100 24
8 10.0925052 100nm24 100 24
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Table 4.7: Significance values of change in PS2 expression in response to E2
treatment. **=p<0.01.
Response: ps2
Df Sum Sq Mean Sq F value Pr(>F)
dose 1 13.290 13.29 3.1293 0.151619
time 1 105.063 105.063 24.7393 0.007631 **
dose:time 1 105.063 105.063 24.7393 0.007631 **
Residuals 4 16.987 4.247
0nm12 0nm24 100nm12 100nm24
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Figure 4.48: Boxplot for PS2 in E2 treated cells.
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Table 4.8 and 4.9 shows fold changes in ANLN expression in response to
E2 treatment in MCF7 cells and their significance values according to dose,
time and dose:time. ANLN expression significantly increases in response to
E2 treatment in time and dose:time (p<0.05) tests. Figure 4.49 shows the
boxplot of the results. Since the interaction component is significant, the
response to E2 in time differs such that it is greater at a later time point
(i.e., 24 hr vs. 12h).
Table 4.8: Log2-fold changes of ANLN in response to E2 treatment.
ANLN group dose time
1 0.3636003 0nm12 0 12
2 -0.3636003 0nm12 0 12
3 -0.9847162 100nm12 100 12
4 -0.2755195 100nm12 100 12
5 -0.6605048 0nm24 0 24
6 0.6605048 0nm24 0 24
7 2.9312232 100nm24 100 24
8 2.0400052 100nm24 100 24
Table 4.9: Significance values of change in ANLN expression in response to E2
treatment. *=p<0.05.
Response: Anln
Df Sum Sq Mean Sq F value Pr(>F)
dose 1 1.7214 1.7214 3.8563 0.121
time 1 4.8539 4.8539 10.8737 0.03 *
dose:time 1 4.8539 4.8539 10.8737 0.03 *
Residuals 4 1.7856 0.4464
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Figure 4.49: Boxplot for ANLN in E2 treated cells.
Table 4.10 and 4.11 shows fold changes in total CHRNA5 expression in re-
sponse to E2 treatment in MCF7 cells and their significance values accord-
ing to dose, time and dose:time. They show that total CHRNA5 expression
significantly increases in response to E2 treatment in time dose:time test
(p<0.05). Figure 4.50 shows the boxplot of the results. This findings is sim-
ilar to that about ANLN; again CHRNA5 expression is different across time
points since the effect of E2 is more prominent at 24h.
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Table 4.10: Log2-fold changes of total CHRNA5 in response to E2 treatment.
A5.all group dose time
1 0.2811003 0nm12 0 12
2 -0.2811003 0nm12 0 12
3 -0.1922162 100nm12 100 12
4 -2.2830195 100nm12 100 12
5 -0.4230048 0nm24 0 24
6 0.4230048 0nm24 0 24
7 2.6237232 100nm24 100 24
8 2.7025052 100nm24 100 24
Table 4.11: Significance values of change in total CHRNA5 expression in re-
sponse to E2 treatment. *=p<0.05.
Response: A5.all
Df Sum Sq Mean Sq F value Pr(>F)
dose 1 1.0160 1.016 1.5026 0.28751
time 1 7.6078 7.6078 11.2513 0.02846 *
dose:time 1 7.6078 7.6078 11.2513 0.02846 *
Residuals 4 2.7047 0.6762
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Figure 4.50: Boxplot for all variants of CHRNA5 in E2 treated cells.
Table 4.12 and 4.13 shows fold changes in 1000bp CHRNA5 expression in re-
sponse to E2 treatment in MCF7 cells and their significance values according
to dose, time and dose:time. They show that 1000bp CHRNA5 expression
significantly increases in response to E2 treatment in dose test (p<0.01).
Figure 4.51 shows the boxplot of the results. Interestingly, 1000bp isoform
of CHRNA5 behaves differently than all forms in the sense that E2 exhibits
effect at 12h although to a lesser degree than 24h.
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Table 4.12: Log2-fold changes of 1000bp variant of CHRNA5 in response to E2
treatment.
1000bpA5 group dose time
1 -0.3338997 0nm12 0 12
2 0.3338997 0nm12 0 12
3 0.8077838 100nm12 100 12
4 1.7169805 100nm12 100 12
5 0.1469952 0nm24 0 24
6 -0.1469952 0nm24 0 24
7 2.0287232 100nm24 100 24
8 1.6275052 100nm24 100 24
Table 4.13: Significance values of change in 1000bp CHRNA5 expression in re-
sponse to E2 treatment. **=p<0.01.
Response: 1000bp
Df Sum Sq Mean Sq F value Pr(>F)
dose 1 4.7756 4.7756 25.1346 0.00742 **
time 1 0.1600 0.16 0.8422 0.41069
dose:time 1 0.1600 0.16 0.8422 0.41069
Residuals 4 0.7600 0.19
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Figure 4.51: Boxplot for 1000bp variant of CHRNA5 in E2 treated cells.
Table 4.14 and 4.15 shows fold changes in 200bp CHRNA5 expression in re-
sponse to E2 treatment in MCF7 cells and their significance values according
to dose, time and dose:time. They show that 200bp CHRNA5 expression has
an approaching significance in response to E2 treatment in dose test (p<0.1).
Figure 4.52 shows the boxplot of the results. E2 is equally effective at 12h and
24h for 200bp variant of CHRNA5 since no significance is seen in time and
the interaction component of ANOVA table is also insignificant, emphasizing
that there is no differential effect of dose at different times.
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Table 4.14: Log2-fold changes of 200bp variant of CHRNA5 in response to E2
treatment.
200bp group dose time
1 0.5261003 0nm12 0 12
2 -0.5261003 0nm12 0 12
3 3.2477838 100nm12 100 12
4 0.1719805 100nm12 100 12
5 -0.9580048 0nm24 0 24
6 0.9580048 0nm24 0 24
7 2.8437232 100nm24 100 24
8 3.2675052 100nm24 100 24
Table 4.15: Significance values of change in 200bp CHRNA5 expression in re-
sponse to E2 treatment. .=p<0.1.
Response: 200bp
Df Sum Sq Mean Sq F value Pr(>F)
dose 1 11.3549 11.3549 6.3002 0.06606 .
time 1 0.9055 0.9055 0.5024 0.51757
dose:time 1 0.9055 0.9055 0.5024 0.51757
Residuals 4 7.2092 1.8023
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Figure 4.52: Boxplot for 200bp variant of CHRNA5 in E2 treated cells.
Table 4.16 and 4.17 shows fold changes in isoform2 CHRNA5 expression in
response to E2 treatment in MCF7 cells and their significance values accord-
ing to dose, time and dose:time. There is a dose effect such that 100nM of
E2 is effective on expression of isoform2 of CHRNA5 while this effect is time
dependent (p<0.05) and the interaction is also significant, supporting this.
Figure 4.53 shows the boxplot of the results.
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Table 4.16: Log2-fold changes of isoform2 of CHRNA5 in response to E2 treat-
ment.
iso2 group dose time
1 -0.05889974 0nm12 0 12
2 0.05889974 0nm12 0 12
3 1.63278379 100nm12 100 12
4 1.34198051 100nm12 100 12
5 -0.21050476 0nm24 0 24
6 0.21050476 0nm24 0 24
7 2.69622324 100nm24 100 24
8 3.34500519 100nm24 100 24
Table 4.17: Significance values of change in isoform2 CHRNA5 expression in re-
sponse to E2 treatment. ***=p<0.001, *=p<0.5.
Response: iso2
Df Sum Sq Mean Sq F value Pr(>F)
dose 1 10.1610 10.161 116.689 0.0004166 ***
time 1 1.1754 1.1754 13.498 0.0213175 *
dose:time 1 1.1754 1.1754 13.498 0.0213175 *
Residuals 4 0.3483 0.0871
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Figure 4.53: Boxplot for isoform 2 of CHRNA5 in E2 treated cells.
Table 4.18 and 4.19 shows fold changes in isoform3 CHRNA5 expression in
response to E2 treatment in MCF7 cells and their significance values ac-
cording to dose, time and dose:time. They show that isoform3 CHRNA5
expression significantly increases in response to E2 treatment in dose test
(p<0.05), independent of time. Figure 4.54 shows the boxplot of the results.
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Table 4.18: Log2-fold changes of isoform3 of CHRNA5 in response to E2 treat-
ment.
iso3 group dose time
1 0.1536003 0nm12 0 12
2 -0.1536003 0nm12 0 12
3 2.0352838 100nm12 100 12
4 0.4294805 100nm12 100 12
5 -0.9830048 0nm24 0 24
6 0.9830048 0nm24 0 24
7 3.3487232 100nm24 100 24
8 3.1325052 100nm24 100 24
Table 4.19: Significance values of change in isoform3 CHRNA5 expression in re-
sponse to E2 treatment. *=p<0.05.
Response: iso3
Df Sum Sq Mean Sq F value Pr(>F)
dose 1 10.0038 10.0038 12.1536 0.02521 *
time 1 2.0165 2.0165 2.4498 0.19259
dose:time 1 2.0165 2.0165 2.4498 0.19259
Residuals 4 3.2925 0.8231
91
0nm12 0nm24 100nm12 100nm24
-1
0
1
2
3
Group
Fo
ld
 C
ha
ng
e
iso3 A5
Figure 4.54: Boxplot for isoform 3 of CHRNA5 in E2 treated cells.
The summary of the data in Tables 4.6 to 4.19 can be seen in Table 4.20
Table 4.20: 2-way ANOVA results for all genes.
Genes dose time dose:time
PS2 0.151619 0.007631 0.007631
ANLN 0.121 0.03 0.03
CHRNA5_All 0.28751 0.02846 0.02846
1000bp CHRNA5 0.00742 0.41069 0.41069
200bp CHRNA5 0.06606 0.51757 0.51757
iso2 CHRNA5 0.0004166 0.0213175 0.0213175
iso3 CHRNA5 0.02521 0.19259 0.19259
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4.3.2 ANCOVA of CHRNA5 expression
ANCOVA was done in Matlab in order to see if there is a difference in the
trends of response to E2 between 12h and 24h. Figures 4.55 to 4.59 show
ANCOVA graphs and tables for each of the 5 CHRNA5 primers. A signif-
icant p-value for the slope indicates that there is a dose effect of E2, while
a significant p-value between groups indicates that there is a time effect for
CHRNA5 and the expression levels of the target genes differ between 12h
and 24h.
In ANCOVA, separate lines were assumed since each time point has its own
controls and these respective controls were used in ∆∆Ct calculations for
12h and 24h.
Total CHRNA5 expression is not significantly altered with 100nM E2 treat-
ment, but the significant p-value (p<0.05) shows that total CHRNA5 expres-
sion significantly differs between 12h and 24h E2 treatment.
The expression of 1000bp CHRNA5 variant is highly significantly altered with
100nM E2 treatment (p<0.01), but this effect seems to be time-independent.
The expression of 200bp CHRNA5 variant is altered with a trend toward
significance (p=0.0661) with 100nM E2 treatment, but this trend seem to be
time-independent.
The expression of isoform2 of CHRNA5 variant is highly significantly al-
tered with 100nM E2 treatment (p<0.001), and this effect seems to be time-
dependent, since the p-value (p<0.05) indicates that the expression is signif-
icantly different between 12h and 24h of treatment.
The expression of isoform3 of CHRNA5 variant is significantly altered with
100nM E2 treatment (p<0.05), but this effects seem to be time-independent.
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Figure 4.55: ANCOVA of CHRNA5_All in response to E2 treatment. 1 (red)
refers to 12h of treatment and 2 (blue) refers to 24h of treatment,
respectively.
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Figure 4.56: ANCOVA of 1000bp CHRNA5 in response to E2 treatment. 1 (red)
refers to 12h of treatment and 2 (blue) refers to 24h of treatment,
respectively.
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Figure 4.57: ANCOVA of 200bp CHRNA5 in response to E2 treatment. 1 (red)
refers to 12h of treatment and 2 (blue) refers to 24h of treatment,
respectively.
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Figure 4.58: ANCOVA of iso2 CHRNA5 in response to E2 treatment. 1 (red)
refers to 12h of treatment and 2 (blue) refers to 24h of treatment,
respectively.
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Figure 4.59: ANCOVA of iso3 CHRNA5 in response to E2 treatment. 1 (red)
refers to 12h of treatment and 2 (blue) refers to 24h of treatment,
respectively.
4.3.2.1 Saturation Points of E2 Treatment
In order to determine whether 100nM is the saturation point of expressions
of the genes of interest or a lower concentration is sufficient, we added 30nM
E2-treated samples to our analysis. Although the 30nM E2-treated samples
lack their own control, they will give us an idea about how to proceed in our
future studies with E2.
Figures 4.60 to 4.64 shows the graphs of the analysis. These results indicate
that effects of E2 treatment on gene expression is always more prominent at
24h. There is a decrease in expression of the total CHRNA5 amount at 12h,
but apart from that both 12h and 24h of E2 treatment increased expression of
CHRNA5 variants. Results indicate that gene expression levels are saturated
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before the concentration is increased to 100nM.
Figure 4.60: Expression levels of all isoforms of CHRNA5 in response to E2
treatment
Figure 4.61: Expression levels of 1000bp isoform of CHRNA5 in response to E2
treatment
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Figure 4.62: Expression levels of 200bp isoform of CHRNA5 in response to E2
treatment
Figure 4.63: Expression levels of isoform 2 of CHRNA5 in response to E2 treat-
ment
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Figure 4.64: Expression levels of isoform 3 of CHRNA5 in response to E2 treat-
ment
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Chapter 5
CONCLUSION AND DISCUSSION
Abnormal or aberrant alternative splicing was previously associated with a
variety of diseases, including cancer. Abnormal splicing of pre-mRNAs can
lead to malignancy by the production of ‘unnatural’ variants that are not
normally present in a tissue type, or by changing the normal ratio between
natural variants in a specific tissue.46,47
CHRNA5 is a subtype of cholinergic nicotinic alpha receptors, that has been
implicated in smoking behavior, cognitive performance, and more recently in
lung cancer.36–39 CHRNA5 was also found to be alternatively spliced in cell
lines, normal lung tissue and lung adenocarcinoma.43,73 The expression levels
of CHRNA5 isoforms were shown to be increased in lung cancer.43 In light
of these findings, we investigated alternative splicing patterns of CHRNA5
as well as the response of some of these splicing variants to serum starvation
and β-estradiol treatment.
To this end, we choose 10 different breast cancer cell lines belonging to 3
different molecular subtypes HER2+, Luminal and Basal.22,24,25
Serum starvation treatment has been used for a long time in experimental
setups to obtain synchronized cells. It has also been used in studies dealing
with gene expression regulation, apoptosis and stress response of cells.62 We
investigated the effects of serum starvation of cell viability using MTT assay.
Our results showed that all of the cell lines, except MCF7 and T47D, re-
sponded to serum starvation with a decrease in cell viability. It is interesting
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that both of the cell lines that did not respond have very similar characteris-
tics (Table 3.1) and belonged to the same molecular subtype (Table 1.3). This
might be due to a specific response of the molecular subtype, or a possible
resistance to starvation that these cell lines obtained in culture conditions.
We then decided to investigate how the two variants of CHRNA5 responded
to serum starvation in breast cancer cell lines. For our serum starvation ex-
periments, we used 2 different sets for each cell line, including 2 biological
replicates each for 10% FBS treatment and 0.1% FBS treatment. This al-
lowed us to have two batches from each cell line, with 4 samples each.
First, using regular PCR, we identified the splice variants of CHRNA5 among
these cell lines using primers that can amplify all of the variants separately.
This implicated that there was a difference in expression of different CHRNA5
isoforms between breast cancer cell lines. However when we tried to see these
differences using variant-specific primers with regular PCR, we were not able
to visualize the changes. To overcome this, we decided to proceed to qPCR
in order to quantify the differences. We chose two of the variants (200bp
variant and 1000bp variant) for qPCR analysis.
We designed our qPCR experiments so that a single batch was run on a
single plate. 4 samples from each cell line (2 controls and 2 treatment sam-
ples) were run in duplicates on the same plate, resulting in 80 data points.
2 qPCR runs were done for each gene, bringing the number of data points
to 160 per batch. Having a bigger sample size with technical and biological
replicates enables us to estimate the statistical significance of the results with
a higher confidence level.63–65 Since the sample size is relatively big, qPCR
experiments are prone to sample-to-sample or run-to-run variations that can
be due to biological variation of samples or technical errors in experimental
steps.63,67,68 The presence of this variability calls for a normalization so that
the effects of a particular treatment can be assessed correctly.
Due to the nature of qPCR (high number of experimental steps, variables
and sample size) there might be some data points that do not represent the
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normal distribution of the data. Identification and exclusion of these data
points is important to obtain statistically meaningful results.66 Since we have
multiple runs as well as technical and biological replicates, our data qualified
for outlier detection and exclusion.70 Several outlier detection methods were
proposed. In our study we used a method that was similar to that of Burns
et. al, (2005), in which we used boxplots to identify data points that fell
outside around 99% range of the data. Among a total of 1280 data points
analyzed, 45 data points were identified as potential outliers, and 41 of them
were replaced. This corresponds to an error rate of 3.2% for the whole serum
starvation data. It is important to note that these potential outliers were
detected with the default parameters in IQR of Matlab. To identify the prob-
able outlier values with a statistical significance, a more stringent test may
be employed. To this end, Grubb’s test was suggested in order to identify
the data points that differ from the rest of that data set with significance.66
For normalization we chose two genes (TPT1 and SDHA) as reference, and
took the geometric means of the expression values of these two genes, as
previously suggested.63,64
Scatter plots and ANCOVA of 200bp and 1000bp CHRNA5 variants showed
that expression of these variants were correlated in breast cancer cell lines,
both in 10% and 0.1% FBS treated cells. This suggests that 200bp and
1000bp variants of CHRNA5 are co-regulated or regulated similarly in breast
cancer cells. The expression levels of the 2 isoforms groups the breast cancer
cell lines and this grouping correlates with the molecular subtypes of breast
cancer cell lines. HER2 positive cell lines MDA MB 361 and MDA MB 468
seem to have the lowest CHRNA5 expression, while cell lines belonging to
the basal type, MDA MB 468 and BT-20 have the highest CHRNA5 expres-
sion, especially for the 1000bp variant. The cell lines in the luminal subtype
and basal cell lines MDA MB 231 and MDA MB 157 have expression values
between the two.
We have expression data from two different batches of the same cell lines.
Our sample size enables us to assess and get rid of the batch effect. For
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this we used ANCOVA. This method takes the reference gene expression,
which is the geometric mean of TPT1 and SDHA, as a covariate and tests
the differences in response to treatment among cell lines. We assumed that
the reference genes would behave similarly among cell lines, hence we used
parallel lines to assess the covariance. The outcome of the ANCOVA is two
p-values, one for the significance of the treatment and the other for the cor-
relation of reference gene with the target gene. The second p-value is given
as the p-value of the slope. In some of our data, p-values of the slopes
are significant (p<0.05), which implies that reference gene expression varies
between cell lines. This suggests that TPT1 and SDHA may vary only a
limited degree between samples since the Ct values for reference genes are
around 17 and 19.5 and those for the target transcripts are between 21 and
29. Thus, geometric average of TPT1 and SDHA is a reasonable estimate of
RNA amount used in the tests.
When we analyzed the starvation response separately for each cell line, we
considered a p value below 0.05 significant and a p value below 0.15 to have
a trend. In 200bp CHRNA5 variant, only ZR-75-1 and MDA MB 157 cells
showed a significant alteration in response to starvation and only HCC-1937
cells seemed to have trend toward a change. In 1000bp CHRNA5 variant
none of the cell lines showed a significant alteration but 4 cell lines had
trends toward a change. This might be due to the batch effect, or due to
inappropriate choice of reference genes. Another possibility is that CHRNA5
may not be highly responsive to serum starvation so that we are not able to
detect these small changes in expression. Serum starvation treatment may be
repeated for the cell lines that showed promising results, that is those with
a trend toward change, with a p value below 0.15, using a higher number of
samples within a batch in order to increase statistical power.
While we tried a variety of other statistical analyses such as t-test (data not
shown), we decided that ANCOVA was the one that was the most appro-
priate for the nature of our data set. But other analysis methods, such as
two-way ANOVA can also be used to analyse this data.
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Estrogen has previously been associated with both the initiation and the
progression of breast carcinogenesis.13–15 Estrogens were also shown to reg-
ulate the expression of a variety of genes, having primary and secondary
targets.16,19,84 To this end, we wanted to see if CHRNA5 expression was
E2-responsive and used ER+, estrogen-responsive MCF7 cell line. To see if
E2 treatment was effective, we used PS2 and ANLN which were shown to
be primary target and secondary targets of E2, respectively.19,74 Among the
5 variants of CHRNA5 that were tested (total CHRNA5, 200bp CHRNA5,
1000bp CHRNA5, CHRNA5 isoform2 and CHRNA5 isofrom3), all of the
variants, except total CHRNA5, showed a significant difference in expression
with 100nM E2 with ANCOVA while total CHRNA5 expression was shown
to be significantly different between 12h and 24h time points. Whereas 2-way
ANOVA results showed a significant difference in 1000bp CHRNA5, isoform2
CHRNA5 and isoform3 CHRNA5 with 100nM E2 treatment. Interestingly,
total CHRNA5 expression seems to have a delayed response, and no increase
in expression can be seen at 12h, which is not the case for any of the other
variants (although at a lower level, they show increased expression at 12h
also)
We also have 30nM E2-treated samples. Even though they lack their own
controls, we decided to add the data from those samples to our analysis to
estimate the saturation concentration for E2 (i.e. the E2 concentration that
is sufficient to generate the highest response for a given gene). This analysis
showed us that saturation can be reached with a lower concentration than
100nM, so in order to assess the effects of E2 on CHRNA5 expression more
precisely, a dose curve consisting of 0nM, 1nM, 10nM, 30nM and 100nM can
be used in future experiments.
Our data shows that 200bp and 1000bp variants of CHRNA5 are regulated
similarly in breast cancer cell lines. The two variants respond differently to
serum starvation treatments in different cell lines. A larger sample size may
be required to assess the changes in expression of different CHRNA5 variants
in breast cancer cell lines with different molecular subtypes.
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Chapter 6
FUTURE PERSPECTIVES
In order to get a dataset that is more statistically significant, additional
treatments on cell lines from the same batch can be done. This will increase
the sample size and allow us to have statistical data with more confidence.
In order to determine whether the potential outliers that we identified using
boxplot function of Matlab are true outliers, Grubb’s test, modified for mul-
tiple outliers, can be used to identify the data points among these potential
outliers that significantly differ from the rest of the data set.
Changes in proliferation that were recorded with MTT assay might be checked
to see if they correlate with changes in CHRNA5 expression in response to
serum starvation.
There are additional variants of CHRNA5, other than the ones that we chose
to focus on this study. Primers that are specific to these other CHRNA5
isoforms should be tested in order to get a more complete and accurate un-
derstanding of alternative splicing of CHRNA5 in breast cancer cell lines.
Adding normal breast cell lines to our panel would show us if the expression
ratios of different CHRNA5 variants change in breast cancer, compared to
that of normal breast.
To get a broader idea of the regulation of CHRNA5 in humans, expression in
normal human tissues, especially breast tissue should be investigated. cDNA
panels can be used for this purpose. To see if the results obtained from our
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cell line and cDNA panel studies are compatible in a clinical level, samples
from normal breast tissue and patient tumor samples should be investigated
for CHRNA5 variant expression.
E2-treatment is a promising aspect that affects CHRNA5 expression. In or-
der to solidify these results further we should be able to repeat them with a
cell line that is similar to MCF7 (e.g: T47D). E2 response of the cell lines
that are ER-, like MDA MB 231, should also be investigated.
A dose curve for E2 treatment will give us a better idea of the E2 level
necessary to induce and increase in CHRNA5 expression. Co-treatment of
E2 with its competitors, such as tamoxifen can be done in order to see if
CHRNA5 will respond differently. In addition, E2 treatment can be tried in
CHRNA5-silenced and -overexpressing cells to investigate how the responses
differ from that of controls.
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Chapter 7
APPENDICES
Appendix A
Matlab Codes Used For Analyses
Matlab codes that were used in this study are for:
• Outlier detection and exclusion
• taking arithmetic and geometric means of references
• ANCOVA for all cell lines
• ANCOVA for separate cell lines
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Table 7.1: Matlab code for outlier detection and exclusion
function [data1]=outlier(data)
data=xlsread(’200bp set3-4 run1-2’) %input:data; a 80x2 matrix that contains the
the qPCR measurements from a cell line, for a total of 10 cell lines. Each cell
line has 2 groups and each group has two biological replicates and 2 technical
replicates
j=1
data1=[]; % creates a vector
boxdata=zeros(16,10); % creates an array of all zeroes (16 by 10)
for i=1:10
boxdata
data1
a=[data(j:j+7,1);data(j:j+7,2)] % collects the data for each cell line from 2
separate runs
j=j+8
figure()
boxplot(a) % draws a boxplot for each cell line, showing the outliers
boxdata(:,i)=a;
h = findobj(gcf,’tag’,’Outliers’); % gets the handles of the boxplots for
’Outliers’
yc= get(h,’YData’); % gets the index of the outliers
d=find(a(:,1)==yc(1,:)); % finds the index of the ouliers in our data
d
a(d)=NaN % replaces the outliers with ‘NaN’
data1=[data1;[a(1:8) a(9:16)]]
data1
data1
boxdata
end
data1
boxdata
boxplot(boxdata)
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Table 7.2: Matlab code for arithmetic mean and geometric mean of references
function[]=geomeans(temp);
temp=xlsread(’covdesc.xls’);
ref1=uigetfile(’*.csv’,’ref1’);
ref1=csvread(ref1);
ref2=uigetfile(’*.csv’,’ref2’);
ref2=csvread(ref2);
i1=find(temp(:,4)==1);
i2=find(temp(:,4)==2);
ref1m=nanmean(ref1,2);
ref2m=nanmean(ref2,2);
ref1_means=[ref1m(i1,:),ref1m(i2,:)];
ref2_means=[ref2m(i1,:),ref2m(i2,:)];
m=nanmean(ref1_means,2);
n=nanmean(ref2_means,2);
a=[m,n]
b=geomean(a,2)
xlswrite(’Refset12’, b)
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Table 7.3: Matlab code for ANCOVA of all cell lines
function[]=aoccl(trg,ref);
trg=uigetfile(’*.csv’,’trg’);
trg=csvread(trg);
ref=csvread(’Ref01.csv’);
g=repmat(1:10,[4 1]);
g=g(:)’;
[h,a,c,s]=aoctool(ref,trg,g,”,...
”,”,”,”,’parallel lines’)
123
Table 7.4: Matlab code for ANCOVA of separate cell lines
function[]=aoc(temp,data);
temp2=xlsread(’temp2.xls’);
ref12=uigetfile(’*.csv’,’ref12’);
ref12=csvread(ref12);
trg12=uigetfile(’*.csv’, ’trg12’);
trg12=csvread(trg12);
ref34=uigetfile(’*.csv’,’ref34’);
ref34=csvread(ref34);
trg34=uigetfile(’*.csv’, ’trg34’);
trg34=csvread(trg34);
for i=1:10
i3=find(temp2(:,1)==i)
a=trg12(i3)
b=trg34(i3)
c=ref12(i3)
d=ref34(i3)
e=[a;b]
f=[c;d]
g=[1 1 0 0 1 1 0 0 ]’;
[h,a,c,s]=aoctool(f,e,g,”,...
”,”,”,”,’parallel lines’)
end
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Appendix B
Expression values of TPT1 and SDHA
probesets in analyzed GSE datasets
Figure 7.1: Expression values of TPT1 probeset in GSE21648 dataset in control
and starvation groups
Figure 7.2: Expression values of SDHA probeset in GSE21648 dataset in control
and starvation groups
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Figure 7.3: Expression values of TPT1 probeset in GSE31040 dataset in control
and starvation groups
Figure 7.4: Expression values of SDHA probeset in GSE31040 dataset in control
and starvation groups
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Figure 7.5: Expression values of TPT1 probeset in GSE1692 dataset in control
and starvation groups
Figure 7.6: Expression values of SDHA probeset in GSE1692 dataset in control
and starvation groups
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Figure 7.7: Expression values of TPT1 probeset in GSE8597 dataset in control
and estradiol treatment groups
Figure 7.8: Expression values of SDHA probeset in GSE8597 dataset in control
and estradiol treatment groups
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